Programme Inflammatory and Cardiovascular Disorders

Programme

Inflammatory and Cardiovascular

Disorders

2 IMIM 2019 Hospital del Mar Medical Research Institute > SUMMARY

Programme DirectorFrancesc Xavier Nogués Solan

RESEARCH GROUPS

B Cell Biology Andrea Cerutti

Biomedical Research in Heart Diseases Núria Farré

Cell Research on Inflammation and Cartilage Jordi Monfort

Critical Illness Joan Ramon Masclans

Hepatologic Research Montserrat García

Immunity and Infection José Miguel López-Botet

Infectious Pathology and Antimicrobials Juan Pablo Horcajada

Inflammatory and Neoplastic Dermatological Diseases Ramon Maria Pujol

Kidney Disease Julio Pascual

Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer Esther Barreiro

Musculoskeletal Research Francesc Xavier Nogués

Myogenesis, Inflammation & Muscle Function Joaquim Gea

Neuroimmunology Jose Enrique Martínez

Neurovascular Jaume Roquer

Rehabilitation Esther Duarte

Inflammatory and Cardiovascular Disorders

15 Research groups

185 Professionals

57 Research projects

318 Publications

Programmes

> SUMMARY IMIM 2019 Hospital del Mar Medical Research Institute 3

Inflammatory and Cardiovascular Disorders Programme

The Research in Inflammatory and Cardiovascular Disorders (RICAD) programme currently gathers fifteen groups, mostly led by researchers from Parc de Salut MAR with clinical duties, including two with recognized expertise in Immunology. Scientific interests are oriented to the study of a variety of disorders involving inflammatory processes in their pathophysiology. On the other hand, knowledge on the molecular basis of inflammation is promoting the development of novel therapeutic approaches with an impact in other health problems (e.g. cancer, neurodegenerative disorders), thus fostering internal collaborations between different IMIM programmes.

Among such a diversity of research lines, those more competitive and aligned with hospital health care priorities receive a special consideration in the framework of the institutional strategic plan. Internal seminars aimed to promote communication between the different groups are organized monthly. Established researchers have specific space assigned at IMIM premises, facilitating their interaction with other institutions located at the Barcelona Biomedical Research Park (PRBB), as well as access to shared infrastructures and core facilities. Currently, laboratory space constraints become a limitation for integrating new researchers and the development of emerging groups.

Overall, RICAD satisfactorily contributed to IMIM achievements according to the rate/visibility of indexed publications, competitive fund raising and reinvestment of clinical trials income to support academic research. Most RICAD groups participate in national research ISCIII networks (RETICs, CIBERs), training PhD students and medical residents. An increase of productive collaborations, both internal and across other IMIM programmes (i.e. Cancer), is reflected by co-authored publications. An effort to further enhance leadership/visibility in publications, internationalization and transfer activities is warranted.


Members of the B Cell Biology research group use different cellular, histological, and molecular techniques to address basic questions related to B cell activation and antibody production. B cells are a lymphocyte subset that repels foreign pathogens and controls endogenous commensal microbes by producing antibodies, also termed immunoglobulins (Igs). We are especially interested in a process called Ig heavy chain class switching. By replacing IgM with IgD, IgG, IgA or IgE, class switching provides antibodies with novel effector functions without changing their antigen specificity. In general, our goal is to dissect the mechanisms by which different subsets of systemic and mucosal B cells regulate class switching and antibody production during humoral responses to commensal or pathogenic microbes. We are also interested in the clonal architecture of these B cell responses.

Group LeaderAndrea Cerutti

(ICREA Professor)

[email protected]

Members

Giuliana Magri (Researcher)Roser Tachó Piñot (Technician)Sonia Tejedor Vaquero (Technician)

> Inflammatory and Cardiovascular Disorders

B Cell Biology RESEARCH GROUP


Inflammatory and Cardiovascular Disorders B Cell Biology

Main Publications

• Galindo-Campos MA, Bedora-Faure M, Farrés J, Lescale C, Moreno-Lama L, Martínez C, Martín-Caballero J, Ampurdanés C, Aparicio P, Dantzer F, Cerutti A, Deriano L, Yélamos J. 2019, Coordinated signals from the DNA repair enzymes PARP-1 and PARP-2 promote B-cell development and function. Cell Death and Differ 2019 Dec; 26 (12): 2667-2268. IF 8.086. D1.

See all Publications

Ongoing Research Projects

• Gut plasma cell responses in health and IBD (Retos grant) - Financing institution: Ministerio de Educación y Ciencia (RTI2018-093894-B-I00)- Period: from 2018 to 2021- Principal investigator: Cerutti, Andrea

• Humoral responses in the respiratory mucosa: role of IgD - Financing institution: Ministerio de Educación y Ciencia (SAF2014-52483R)- Period: from 2015 to 2019- Principal investigator: Cerutti, Andrea

See all Projects

Appointments

• Andrea Cerutti. Member of the ERC Consolidator Grant Evaluation 2019, Panel LS6. European Research Council. 14-16/05/19 (Step 1).

• Andrea Cerutti. Member of the ERC Consolidator Grant Evaluation 2019, Panel LS6. European Research Council. 08-10/10/19 (Step 2).

OutreachConferences, Seminars and Courses

• Andrea Cerutti. Invited speaker. Marginal Zone Lymphoma Scientific Workshop. New York (NY), 17-18 April 2019.

• Andrea Cerutti. Invited speaker. Immunology Seminar Series at the Kennedy Institute of Oxford University. Oxford (UK), 24 February 2019.

• Giuliana Magri. Invited speaker. Immunology Seminar Series. Manchester (UK), 28 February 2019.

https://www.imim.es/programesrecerca/inflamacio/en_bcellbiology.html?n=&any=2019&enviar.x=34&enviar.y=17&t=publicacions&g=71

https://www.imim.es/programesrecerca/inflamacio/en_bcellbiology.html?t=projectes&g=71


The Group of Biomedical Research in Heart Diseases (GREC) focuses on generating new translational research in the field of Cardiovascular Diseases, where bedside unresolved questions generate hypotheses for applied basic and clinical research with potential impact on patient management. The group works in four main areas of cardiology (coronary heart disease, valvular heart disease, arrhythmias, and cardiomyopathies/heart failure), around which it has established three main research areas: 1) identification of biomarkers of cardiovascular diseases; 2) study of the effect of ageing in heart diseases; and 3) application of new technologies in the daily management of cardiac patients.

Group LeaderNúria Farré López

[email protected]

Members

Laia Carla Belarte Tornero (Researcher)Mercè Cladellas Capdevila (Researcher)Paloma Garcimartín Cerezo (Researcher)Julio Martí Almor (Researcher)Aleksandra Mas-Stachurska (Researcher)Lluís Molina Ferragut (Researcher)Marta Tajes Orduña (Researcher)Helena Tizón Marcos (Researcher)Ermengol Vallès Gras (Researcher)Beatriz Vaquerizo Montilla (Researcher)Consol Ivern Díaz (Technician)Alejandro Negrete (Technician)Laia Yáñez Bisbe (Technician)Marta Gimeno López (Research Assistant)


Biomedical Research in Heart DiseasesRESEARCH GROUP


Inflammatory and Cardiovascular Disorders Biomedical Research in Heart Diseases

Main Publications

• Rodríguez-Costoya I, Tizon H, Vaquerizo B, Salvatella N, Martí-Almor J, Millán R. Coronary Lithoplasty: Initial Experience in Coronary Calcified Lesions. Rev Esp Cardiol 2019; 72(9): 788-790. FI 5.126. Q1.

• Ruiz-Bustillo S, Ivern C, Badosa N, Farré N, Marco E, Bruguera J, Cladellas M, Enjuanes C, Cainzos-Achirica M, Martí-Almor J, Comín-Colet J. Efficacy of a nurse-led lipid-lowering secondary prevention intervention in patients hospitalized for ischemic heart disease: A pilot randomized controlled trial. Eur J Cardiovasc Nurs 2019; 18(5): 366-374. FI 2.497. Q1.

• Vallès E, Benito B, Jiménez J, Cabrera S, Alcalde O, Altaba C, Guijo MA, Fan R, Martí-Almor J. Double factor single shot to diminish complications in cryoballoon ablation procedures for atrial fibrillation. J Interv Card Electrophysiol 2019; 55(1): 17-26. FI 1.534. Q4.

• Garcimartín P, Pardo Y, Verdú JM, Delgado-Hito P, Astals M, Comín J. Transcultural adaptation into Spanish of the Patient empowerment in long-term conditions questionnaire. Aten Primaria 2019; 51(1): 24-31. FI 1.346. Q3.

• Ribas N, Recasens L, Pérez-Fernández S, Bazan V, Pedro-Botet J, Ruiz-Bustillo S, Elosua R, Martí-Almor J. A new rational approach to reach LDL-cholesterol concentration objectives after an acute coronary syndrome. Clin Investig Arterioscler 2019; 31(3): 93-100.



• Diagnóstico y tratamiento precoz de cardiotoxicidad en pacientes onco-hematológicos en el marco de una unidad multidisciplinar

- Financing institution: Sociedad Española de Cardiología- Period: from 2018 to 2019- Principal investigator: Belarte Tornero, Laia Carla

• Ensayo clínico randomizado: valoración de la intervención multidisciplinar conjunta de cardiólogo y geriatra en pacientes ancianos tras ingreso reciente por insuficiencia cardiaca

- Financiang institution: Beca Primitivo de la Vega. Fundación MAPFRE- Period: from 2017 to 2020- Principal investigator: Farré López, Núria

See all Projects

https://www.imim.es/programesrecerca/inflamacio/en_grupgrec.html?n=&any=2019&enviar.x=33&enviar.y=13&t=publicacions&g=19

https://www.imim.es/programesrecerca/inflamacio/en_grupgrec.html?t=projectes&g=19


Inflammatory and Cardiovascular Disorders Biomedical Research in Heart Diseases

Participation in Research Networks

• CIBERCV. Estudio prospectivo multidisciplinar de nuevos indicadores fenotípicos y pronósticos en pacientes con insuficiencia cardiaca de debut (REDINSCOR III)

- Financing institution: Fondo de Investigación Sanitaria. ISCIII - Period: from 2017 to 2020- Principal investigator: Solé González, Eduard

Clinical Trials Signed in 2019

• A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of CSL112 in Subjects with Acute Coronary Syndrome

- Protocol: CSL112_3001- Sponsor: CSL Behring LLC- Budget: 82,336 €- Principal investigator: Recasens Gracia, Lluís

• Estudio doble ciego, aleatorizado, controlado con placebo, con grupos paralelos de AP30663 administrado por vía intravenosa para cardioversión en pacientes con fibrilación auricular

- Protocol: AP30663 - 2001- Sponsor: Acesion Pharma APS- Budget: 20,915.84 €- Principal investigator: Martí Almor, Julio

• Investigación clínica del sistema de estimulación ENO/TEO/OTO en entornos de IRM (CAPRI)

- Protocol: IBSY06- Sponsor: Sorin CRM SAS- Budget: 18,225 €- Principal investigator: Martí Almor, Julio


• Núria Farré López. III Jornada d’Actualització en la IC. IMIM, Barcelona, 19 November 2019.


RESEARCH GROUP> Inflammatory and Cardiovascular Disorders

Cell Research on Inflammation and Cartilage

Our group comprises multidisciplinary researchers with skills in orthopedic surgery, rheumatology, psychology and biology, with broad experience in clinical and biomedical research in the field of clinical surgery and degenerative diseases. Our research focuses mainly on three areas:

• Study of immune-mediated inflammatory diseases: the studies focus mainly on the search for prognostic markers, improvement of diagnostic imaging techniques to

Group LeaderJordi Monfort Faure

[email protected]

Members

Emma Beltrán Catalán (Researcher)Pedro Benito Ruiz (Researcher)Josep Blanch Rubio (Researcher)Manel Ciria Recasens (Researcher)Santos Martínez Díaz (Researcher)Juan Carlos Monllau García (Researcher)Carolina Pérez García (Researcher)Tarek Carlos Salman Monte (Researcher)Laura Tío Barrena (Researcher)Raúl Torres Claramunt (Researcher)Irene Carrión Barberà (Technician)Jone Llorente Onaindia (Technician)Luciano Polino (Technician)Anna Ribes Mas (Technician)


Inflammatory and Cardiovascular Disorders Cell Research on Inflammation and Cartilage

allow earlier diagnosis and to increase knowledge of the pathophysiology of lupus, fibromyalgia and osteoporosis.

• Knee joint disorders: our group focuses on the study of new approaches in the surgical treatment of knee disorders. The principal areas are biomaterial engineering for partial meniscal and bone replacement, with or without stem cells, and the improvement of surgical approaches to ligament reconstruction, osteotomy and joint prosthesis.

• Study of osteoarthritis physiopathology: our group aims to contribute to expanding knowledge of the processes that take place in the development and progress of the disease by studying the cartilage extracellular matrix and its degradation. We are also involved in developing a new classification of the osteoarthritic patient according to phenotype (clinical, physical, behavior and imaging characteristics) to allow for more personalized therapy. Finally, the group is a pioneer in the study of the central sensitization to pain in this type of patient.

Main Publications

• Aterido A, Cañete JD, Tornero J, Ferrándiz C, Pinto JA, Gratacós J, Queiró R, Montilla C, Torre-Alonso JC, et al. (Pérez C). Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. Ann Rheum Dis 2019; 78(3): e214158. IF 14.299. D1.

• Atienza-Mateo B, Martín-Varillas JL, Calvo-Río V, Demetrio-Pablo R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernández MV, Hernández-Garfella M, et al. Comparative study of infliximab versus adalimumab in refractory uveitis due to Behçet’s disease, National multicenter study of 177 cases. Arthritis Rheumatol 2019; 71(12): 2081-2089. IF 9.002. D1.

• Sanchis-Alfonso V, Ginovart G, Alastruey-López D, Montesinos-Berry E, Monllau JC, Alberich-Bayarri A, Pérez MA. Evaluation of Patellar Contact Pressure Changes after Static versus Dynamic Medial Patellofemoral Ligament Reconstructions Using a Finite Element Model. J Clin Med 2019; 8(12): 2093. IF 5.688. D1.

• Torrente V, Salman-Monte TC, Rúa-Figueroa I, de Uña-Álvarez J, Balboa-Barreiro V, López-Longo FJ, Galindo-Izquierdo M, Calvo-Alen J, Olivé-Marqués A, Mouriño-Rodríguez C, et al., RELESSER Study Group of the Spanish Society of Rheumatology (SER) and the Study Group of Systemic Autoimmune Diseases of the SER (EAS-SER). Relationship between damage and mortality in juvenile-onset systemic lupus erythematosus: Cluster analyses in a large cohort from the Spanish Society of Rheumatology Lupus Registry (RELESSER). Semin Arthritis Rheu 2019; 48(6): 1025-1029. IF 5.072. Q1.

• Pujol J, Ramos-López D, Blanco-Hinojo L, Pujol G, Ortiz H, Martínez-Vilavella G, Blanch J, Monfort J, Deus J. Testing the effects of gentle vibrotactile stimulation on symptom relief in fibromyalgia. Arthritis Res Ther 2019; 21: 148. IF 4.148. Q2.


https://www.imim.es/programesrecerca/inflamacio/en_recercacel.html?n=&any=2019&enviar.x=38&enviar.y=15&t=publicacions&g=36




• Caracterización clínica, radiológica y analítica del paciente con artrosis de rodilla y necesidad de artroplastia

- Financing institution: AEI (DPI2016-80283-C2-2-R)- Period: from 2016 to 2020- Principal investigator: Monllau García, Juan Carlos

• Valoración pronóstica de los valores de los Productos Finales de la Glicación (AGEs) en enfermedades inmunomediadas y comparación con población general

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI18/00059)- Period: from 2019 to 2021- Principal investigator: Salman Monte, Tarek Carlos

• Valoració pronòstica dels valors dels Productes Finals de la Glicació (AGEs) en malalties immunomediates i comparació amb població general

- Financing institution: Societat Catalana de Reumatologia- Period: from 2018 to 2020- Principal investigator: Pérez García, Carolina

• Valoración pronóstica de los valores de los Productos Finales de la Glicación (AGEs) en enfermedades inmunomediadas y comparación con población general

- Financing institution: Fundación Española de Reumatología- Period: from 2019 to 2020- Principal investigator: Salman Monte, Tarek Carlos

See all Projects


• Práctica clínica habitual en España: evaluación del uso de apremilast en pacientes con artritis psoriásica, sin exposición previa a tratamientos biológicos (Estudio PREVAIL)

- Protocol: CEL-APR-2018-01- Sponsor: Celgene, S.L.U.- Budget: 4,482.6 €- Principal investigator: Beltrán Catalán, Emma

• Estudio multinacional, prospectivo y observacional de la eficacia, la utilización de recursos sanitarios y los costes en pacientes con artritis reumatoide que reciben baricitinib, tratamientos modificadores de la enfermedad sintéticos dirigidos o biológicos

- Protocol: I4V-MC-B009- Sponsor: Eli Lilly and Company Limited- Budget: 11,090 €- Principal investigator: Pérez García, Carolina

https://www.imim.es/programesrecerca/inflamacio/en_recercacel.html?t=projectes&g=36



• Estudio fase 3, aleatorizado, doble ciego, que compara risankizumab frente a placebo en pacientes con artritis psoriásica (AP) activa, que han tenido una historia previa de respuesta inadecuada o intolerancia a al menos un fármaco antirreumático modificador de la enfermedad (FAME)

- Protocol: M16-011- Sponsor: FER-MET-2019-01- Budget: 103,544.41 €- Principal investigator: Beltrán Catalán, Emma

• Registro nacional de pacientes con arteritis de células gigantes- Protocol: FER-MET-2019-01- Sponsor: Fundación Española de Reumatología- Budget: 2,800 €- Principal investigator: Salman Monte, Tarek Carlos

• Estudio en fase III, multicéntrico, aleatorizado, doble ciego, de 52 semanas de duración, para comparar la eficacia y la seguridad de GSK3196165 con placebo y con tofacitinib, en combinación con FARME sintéticos convencionales, en participantes con artritis reumatoide con actividad de moderada a intensa que han obtenido una respuesta inadecuada a los FARME sintéticos convencionales o a los biológicos

- Protocol: 201791- Sponsor: GlaxoSmithKline Research & Development Ltd- Budget: 49,164 €- Principal investigator: Pérez García, Carolina

• Evaluación de la seguridad y tolerabilidad del sistema estimulador transcutáneo de Vorso para el tratamiento de pacientes con artritis reumatoide activa y una respuesta inadecuada a los fármacos biológicos modificadores de la enfermedad

- Protocol: VC2018-2- Sponsor: Vorso Corp- Budget: 14,700 €- Principal investigator: Pérez García, Carolina

Awards

• Raúl Torres Claramunt. Professor Palacios y Carvajal Award for the best oral communication presented by a resident doctor 2019. Sociedad Española de Cirugía de Cadera. June 2019.


The Critical Illness Research Group (GREPAC) aims to elucidate the mechanisms involved in the onset and progression of different illnesses that cause a reversible dysfunction in one or more organs, placing the patient’s life at risk. Our research includes clinical research in patients, and also experimental models which allow us to study the molecular mechanisms involved in these processes and to identify therapeutic targets and new strategies.

Group LeaderJoan Ramon Masclans Enviz

[email protected]

Members

Francisco Álvarez Lerma (Researcher)Yolanda Díaz Buendía (Researcher)María Pilar Gracía Arnillas (Researcher)Judith Marín Corral (Researcher)Purificación Pérez Terán (Researcher)Anna Salazar Degracia (Researcher)Antonia Vázquez Sánchez (Researcher)Clara Vilà Vilardell (Researcher)Ana Zapatero Ferrandiz (Researcher)Irene Dot Jordana (PhD Student)Ana Alabart Llinàs (Technician)Thais Guri López (Technician)Rosana Muñoz Bermúdez (Technician)Francisco José Parrilla Gómez (Technician)Marta Gas Amat (Research Assistant)


Clinical IllnessRESEARCH GROUP


Inflammatory and Cardiovascular Disorders Critical Illness

GREPAC understands Critical Care research from a translational, clinical, and multi-disciplinary perspective; therefore GREPAC conducts controlled clinical trials and observational projects of great interest, participating at all possible levels of commitment: as promoters, lead researchers and collaborators in multi-centre projects, as well as developing our own projects.

The research group was recognized by AGAUR (Agència de Gestió d’Ajuts Universitaris i de Recerca, Generalitat de Catalunya) as a research group 2017-2020: Grup de Recerca en Patologia Crítica (SGR 200; Principal investigator: Judith Marín Corral).

Main Publications

• Subirà C, Hernández G, Vázquez-Sánchez A, Rodríguez-García R, González-Castro A, García C, Rubio O, Ventura L, López A, de la Torre MC, Keough E, Arauzo V, Hermosa C, Sánchez C, Tizón A, Tenza E, Laborda C, Cabañes S, Lacueva V, Fernández MM, Arnau A, Fernández R. Effect of Pressure Support vs T-Piece Ventilation Strategies During Spontaneous Breathing Trials on Successful Extubation Among Patients Receiving Mechanical Ventilation: A Randomized Clinical Trial. JAMA 2019; 321(22): 2175-2182. IF 51.273. D1.

• Marín J, Dot I, Boguña M, Cecchini L, Zapatero A, Gracía-Arnillas MP, Pascual S, Vilà C, Castellví A, Pérez-Terán P, Gea J, Masclans JR. Structural differences in the diaphragm of patients following controlled vs assisted and spontaneous mechanical ventilation. Int Care Med 2019; 45(4): 488-500. IF 18.967. D1.

• Roca O, Caralt B, Messika J, Samper M, Sztrymf B, Hernández G, García-de-Acilu M, Frat JP, Masclans JR, Ricard JD. An Index Combining Respiratory Rate and Oxygenation to Predict Outcome of Nasal High Flow Therapy. Am J Respir Crit Care Med 2019; 199(11): 1368-1376. IF 16.494. D1.

• Fernández-Barat L, Motos A, Panigada M, Álvarez-Lerma F, Viña L, López-Aladid R, Ceccato A, Bassi GL, Nicolau DP, López Y, Muñoz L, Guerrero L, Soy D, Israel T, Castro P, Torres A. Comparative efficacy of linezolid and vancomycin for endotracheal tube MRSA biofilms from ICU patients. Crit Care 2019; 23(1): 251. IF 6.959. Q1.

• Luque S, Hope W, Campillo N, Muñoz-Bermúdez R, Sorli L, Barceló-Vidal J, González E, Álvarez-Lerma F, Masclans JR, Montero M, Horcajada JP, Grau S. Population pharmacokinetics of anidulafungin in critically ill patients. Antimicrob Agents Chemother 2019; 63(7): e00378-19. IF 4.715. Q1.


https://www.imim.es/programesrecerca/inflamacio/en_patologia_critica.html?n=&any=2019&enviar.x=38&enviar.y=16&t=publicacions&g=24




• Papel del eje IL-33 /ST2 en el diagnóstico, pronóstico y tratamiento del Síndrome de distrés respiratorio agudo

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI14/01420)- Period: from 2015 to 2019- Principal investigator: Masclans Enviz, Joan Ramon

• Mecanismos moleculares de disfunción diafragmática asociada a ventilación mecánica (VIDD) tras la utilización de modalidades ventilatorias controladas y espontáneas en un modelo humano

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI18/000025)- Period: from 2019 to 2021- Principal investigator: Marín Corral, Judith; Masclans Enviz, Joan Ramon

• Efecto de la ceftarolina sobre la respuesta immunomoduladora y anti-inflamatoria en un modelo murino de neumonía neumocócica

- Financing institution: Sociedad Española de Neumología y Cirugía Torácica (SEPAR)- Period: from 2019 to 2022- Principal investigator: Marín Corral, Judith

See all Projects


• CIBERES: Ciber of Respiratory Diseases

• HISPAFLOW: Spanish Group of Experts in High Flow Oxygen Therapy

• Acute Respiratory Failure – Section Translational Biology Group of the European Society of Intensive Care Medicine (ESICM)

• GETGAG: Spanish Working Group in Severe Influenza A

• GLIMP: Global Initiative for MRSA Pneumonia


• La oxigenoterapia de alto flujo como adyuvante en el tratamiento de la sepsis grave- Protocol: ALT-OXI-2018- Sponsor: Althaia Xarxa Assistencial de Manresa Fundació Privada- Budget: No economic compensation- Principal investigator: Masclans Enviz, Joan

https://www.imim.es/programesrecerca/inflamacio/en_patologia_critica.html?t=projectes&g=24



• A Randomized, Active-Controlled Study to Evaluate the Efficacy and Safety of Intravenous Sulbactam-ETX2514 in the Treatment of Patients With Infections Caused by Acinetobacter Baumannii-Calcoaceticus Complex

- Protocol: CS2514-2017-0004- Sponsor: Entasis Therapeutics- Budget: 28,730 €/patient (no patients included)- Principal investigator: Vázquez Sánchez, Antonia

• Randomized, embedded, multifactorial adaptive platform trial for Community-acquired pneumonia

- Protocol: REMAP-CAP- Sponsor: UMC Utrecht- Budget: 300 €/patient (1 patient included)- Principal investigator: Muñoz Bermúdez, Rosana

Theses

• Díaz Y. “UCI extendida” seguimiento de los pacientes críticos al alta del Servicio de Medicina Intensiva del Hospital del Mar. Universitat Autònoma de Barcelona

- Director: Sancho Insenser, Joan Josep; Navarro Soto, Salvador; Masclans Enviz, Joan Ramon

- Date of defense: 27/11/2019

Appointments

• Joan Ramon Masclans. Teaching Director of the PSMAR. February 2019.

• Joan Ramon Masclans. Member of the Research Commission of the PSMAR. 2019.

• Joan Ramon Masclans. Member of the Governing Board of the PSMAR. 2019.

• Joan Ramon Masclans. President of the Comissió d’aturades of the PSMAR. 2019.

• Joan Ramon Masclans. Secretary of the Organ and Tissue Donation and Transplant Commission

• Recognition by the AQU of two research sections (six years). 5 July 2019.

OutreachDissemination to Society and Initiatives of Citizen Participation

• Judith Marín Corral. Round table on the scientific career. BioJunior. 3 May 2019.



• Judith Marín Corral, Rosana Muñoz. Student of the Font del Ferro Institute visit the Laboratory of the Critical Illness Research Group. ACCÉS Project (Bringing Science Closer to Secondary Schools) included in the Escolab Project. Barcelona Science Programme of the Institute of Culture. 1 March 2019.

• Judith Marín Corral. Talk at the Institut La Salle Barceloneta. International Day of Women and Girls in Science. 11 February 2019.

• Rosana Muñoz, Anna Salazar, Purificación Pérez, Irene Dot. Visit to the Laboratory of the Critical Illness Research Group. Open Day of the Parc de Recerca Biomèdica de Barcelona (PRBB), 5 October 2019.

• Ana Zapatero. Donor’s Day event. Palau Robert, Barcelona. 4 June 2019.

• Judith Marín Corral. Jornada “Posant el pacient en el centre de la recerca”. 21 January 2019.


Since 2000, our research work has been dedicated to different clinical fields in Hepatology: the natural history of decompensated cirrhosis, ascites, renal insufficiency and infections; the virologic response to different therapeutic regimens against hepatitis C; adherence to hepatitis C treatment and the study, prevention and treatment of the psychiatric pathology associated with interferon and the progression of fibrosis in Hepatitis C, with or without HIV coinfection.

Recently, in the era of direct antiviral agents (DAA), we have focused on the treatment of hepatitis C in special populations with many barriers to HCV eradication, such as people with addictions and mental disorders.

We have also initiated different studies in hepatitis B (particularly regarding treatment adherence, predictors of treatment response and disease control and HBV reactivation),

Group LeaderMontserrat García Retortillo

[email protected]

Members

José Antonio Carrión Rodríguez (Researcher)Susana Coll Estrada (PhD Student)Maria Teresa Broquetas González (PhD Student)Núria Cañete Hidalgo (PhD Student)Marc Puigvehí Badosa (PhD Student)Rosa Fernández Rodríguez (Technician)Ana Viu Soto (Technician)Diego Lázaro Agudo (Research Assistant)


Hepatologic Research RESEARCH GROUP


Inflammatory and Cardiovascular Disorders Hepatologic Research

hepatocellular carcinoma (biomarkers, natural history, and impact of different aetiologies) and non-alcoholic steatohepatitis (NASH).

In 2019, our Group joined the LiverScreen Consortium, an international research group aimed to study the prevalence of liver fibrosis in high-risk groups within the general European population.

Main Publications

• Puigvehí M, de Cuenca B, Viu A, Diago M, Turnes J, Gea F, Pascasio JM, Lens S, Cabezas J, Badia E, Olveira A, Morillas RM, Torras X, Montoliu S, Cordero P, Castro JL, Salmerón J, Molina E, Sánchez-Ruano JJ, Moreno J, Antón MD, Moreno JM, de la Vega J, Calleja JL, Carrión JA. Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV-genotype 1b with mild-moderate fibrosis: Results from a Real World Cohort. Liver Int 2019; 39(1): 90-97. IF 5.542. Q1.



• Screening for liver fibrosis. A population-based study in European countries. The “LiverScreen” project

- Financing institution: Gilead Sciences (2018/8284/I) (2019); From January 2020: European Commission (European Union’s Horizon 2020 research and innovation programme) (847989)

- Period: from 2019 to 2024- Principal investigator: García Retortillo, Montserrat

See all Projects


• The Liver Screen Consortium- Financing Institution: Gilead Sciences- Period: from 2019 to 2020 - Principal investigator: García Retortillo, Montserrat

https://www.imim.es/programesrecerca/inflamacio/en_hepatologica.html?n=&any=2019&enviar.x=34&enviar.y=20&t=publicacions&g=25

https://www.imim.es/programesrecerca/inflamacio/en_hepatologica.html?t=projectes&g=25


Inflammatory and Cardiovascular Disorders Hepatologic Research


• Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma- Protocol: 2017-01- Sponsor: Exact Sciences Corporation- Budget: 6,071.62 €- Principal investigator: Coll Estrada, Susana

• Cribaje de fibrosis hepática. Estudio poblacional en Europa. Proyecto “LiverScreen”

- Sponsor: Fundació Clínic per a la Recerca Biomèdica

- Principal investigator: García Retortillo, Montserrat


• Montserrat Garcia Retortillo. Programa multidisciplinari per al tractament de l’hepatitis C en pacients amb addiccions: experiència de l’Hospital del Mar. L’hepatitis C a Barcelona. Objectiu: eliminació 2030. Agència de Salut Pública de Barcelona (ASPB), Barcelona, 15 October 2019.

Dissemination to Society and Initiatives of Citizen Participation

• MT Broquetas González. Malaltia hepàtica per greix, la nova epidèmia que afecta el fetge. Com detectar-la. Què s’ha de fer? Informació als pacients. I Congrés de Pacients Hepàtics. ASSCAT, AMTHC and Albi Espanya. Hotel d’Entitats Can Guardiola, Barcelona, 22 May 2019.

https://youtu.be/vDvys80v9LE





Immunity and InfectionRESEARCH GROUP

The group integrates researchers from IMIM and Pompeu Fabra University (UPF) with extensive experience in the study of human Natural Killer (NK) cell biology. We currently collaborate on the development of two main research areas:

• Characterization of NK cell receptors and their involvement in the response to human cytomegalovirus (HCMV) (J. M. López-Botet). We originally reported that human cytomegalovirus (HCMV) infection promotes to a variable extent a persistent reconfiguration of the human NK cell compartment. We are currently exploring the mechanisms that drive the development of this adaptive NK cell response, addressing its involvement in antiviral defense and putative implications in different settings (e.g. kidney transplantation, cancer, multiple sclerosis), in collaboration with clinical teams.

• NK cells in cancer immunotherapy (A. Muntasell). NK cells can recognize and eliminate transformed cells while shaping the development of tumor-specific adaptive

Group LeaderJosé Miguel López-Botet Arbona

[email protected]

Members

Elisenda Alari Pahissa (Researcher)Ramón Gimeno Martínez (Researcher)Aura Muntasell Castellví (Researcher)Mireia Altadill Balsells (PhD Student)Michelle Ataya Fernández (PhD Student)Anna Rea (PhD Student)Gemma Heredia Díaz (Technician)Sara Raquel Santana Hernández (Technician)

https://www.upf.edu/web/nkiller


Inflammatory and Cardiovascular Disorders Immunity and Infection

immunity. Several mechanisms decreasing NK cell function have been described in cancer patients. Our current projects are aimed at the identification of targetable checkpoints enhancing NK cell anti-tumor responses as well as at exploring the value of phenotypic, genetic and functional NK cell-related variables as biomarkers of response/resistance to treatment in breast and colorectal cancer patients, in collaboration with clinical teams.

Main Publications

• Muntasell A, Rojo F, Servitja S, Rubio-Pérez C, Cabo M, Tamborero D, Costa-García M, Martínez-García M, Menéndez S, Vázquez I, Lluch A, González-Pérez A, Rovira A, López-Botet M, Albanell J. NK Cell Infiltrates and HLA Class I Expression in Primary HER2+ Breast Cancer Predict and Uncouple Pathological Response and Disease-free Survival. Clin Cancer Res 2019; 25(5): 1535-1545. IF 8.911. Q1.

• Muntasell A, Servitja S, Cabo M, Bermejo B, Pérez-Buira S, Rojo F, Costa-García M, Arpí O, Moraru M, Serrano L, Tusquets I, Martínez MT, Heredia G, Vera A, Martínez-García M, Soria L, Comerma L, Santana-Hernández S, Eroles P, Rovira A, Vilches C, Lluch A, Albanell J, López-Botet M. High Numbers of Circulating CD57+ NK Cells Associate with Resistance to HER2-Specific Therapeutic Antibodies in HER2+ Primary Breast Cancer. Cancer Immunol Res 2019; 7(8): 1280-1292. IF 8.619. Q1.

• Deza G, March-Rodríguez A, Sánchez S, Ribas-Llauradó C, Soto D, Pujol RM, Gimeno R, Giménez-Arnau AM. Relevance of the Basophil High-Affinity IgE Receptor in Chronic Urticaria: Clinical Experience from a Tertiary Care Institution. J Allergy Clin Immunol Pract 2019; 7(5): 1619-1626. IF 7.550. Q1.

• Costa-García M, Ataya M, Moraru M, Vilches C, López-Botet M, Muntasell A. Human Cytomegalovirus Antigen Presentation by HLA-DR+ NKG2C+ Adaptive NK Cells Specifically Activates Polyfunctional Effector Memory CD4+ T Lymphocytes. Front Immunol 2019; 10: 687. IF 4.716. Q2.



• Uncovering resistance to monoclonal antibodies in colorectal and breast cancer (J. Albanell, coordinator)

- Financing institution: Proyecto Integrado de Excelencia. ISCIII (PIE 2015/00008) - Period: from 2015 to 2019- Principal investigators: Muntasell, Aura; López-Botet Arbona, José Miguel

https://www.imim.es/programesrecerca/inflamacio/en_receptorscellularsnkiinfecci_.html?n=&any=2019&enviar.x=49&enviar.y=16&t=publicacions&g=54


Inflammatory and Cardiovascular Disorders Immunity and Infection

• Adaptive NK cell-mediated response to cytomegalovirus in the context of immunosuppression: clinical implications in renal transplantation

- Financing institution: Fundació La Marató de TV3 (201822-10) - Period: from 2019 to 2021 - Principal investigator: López-Botet Arbona, José Miguel

See all Projects


• Red Española de Esclerosis Múltiple (REEM)- Financing institution: Fondo de Investigación Sanitaria-ISCIII. Subprograma

RETICS. RD16/0015/0011- Period: from 2017 to 2020- Principal investigators: López-Botet Arbona, José Miguel; Martínez Rodríguez, José

Enrique

Theses

• Cabo M. Role of NK cells in the efficacy of anti-HER2 therapeutic antibodies in breast cancer: from biomarkers to functional checkpoints enhancing ADCC responses. Universitat Pompeu Fabra

- Director: Muntasell Castellví, Aura- Date of defense: 08/11/2019

https://www.imim.es/programesrecerca/inflamacio/en_receptorscellularsnkiinfecci_.html?t=projectes&g=54


Group LeaderJuan Pablo Horcajada

[email protected]

Members

Albert Alier Fabrego (Researcher)Silvia Inés Gómez-Zorrilla Martín (Researcher)Alicia González Mena (Researcher)Santiago Grau Cerrato (Researcher)Ana Guelar Grimberg (Researcher)Roberto Carlos Güerri Fernández (Researcher)Hernando Knobel Freud (Researcher)Elisabet Lerma Chippirraz (Researcher)Emili Letang Jiménez de Anta (Researcher)Inmaculada López Montesinos (Researcher)Sònia Luque Pardos (Researcher)María Milagro Montero (Researcher)Luís Puig Verdié (Researcher)Francisca Sánchez Martínez (Researcher)M. Luisa Sorli Redó (Researcher)Judith Villar García (Researcher)María del Mar Arenas Miras (Technician)Itziar Arrieta Aldea (Technician)Marta de Antonio Cuscó (Technician)Núria Campillo Ambrós (Technician)Núria Carballo Martínez (Technician)Joan Gómez Junyent (Technician)Mònica Jorques Magrans (Technician)


Infectious Pathology and AntimicrobialsRESEARCH GROUP


The group is geared towards the clinical and epidemiological study of the most prevalent or transcendental infectious diseases in the community, such as HIV, pneumonia, urinary tract infections and tuberculosis. In the HIV arena the group is centered in comorbidities, inflammation and microbioma. The group also focuses on infections related to healthcare activities, including those caused by multidrug-resistant microorganisms, osteoarticular and prosthetic infections, and bacteraemia.

A large proportion of the research done by the group focuses on antimicrobial therapy with new and old antibiotics, studying the pharmacokinetics and pharmacodynamics of these drugs and also studying new antimicrobial therapy strategies through clinical trials and observational studies carried out in the group, as main researchers, and collaborators in projects run by the group or multicenter projects.

Main Publications

• Horcajada JP, Montero M, Oliver A, Sorli L, Luque S, Gómez-Zorrilla S, Benito N, Grau S. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin Microbiol Rev 2019; 32(4): e00031-19. IF 17.75. D1.

• Benítez-Cano A, de Antonio-Cuscó M, Luque S, Sorli L, Carazo J, Ramos-Delgado I, Bermejo S, Campillo N, Horcajada JP, Samsó E, Grau S. Systemic pharmacokinetics and safety of high doses of nebulized colistimethate sodium in critically ill patients with hospital-acquired and ventilator-associated pneumonia. J Antimicrob Chemother 2019; 74(11): 3268-3273. IF 5.113. D1.

• Lerma E, Pineda-Moncusí M, González-Mena A, Soldado-Folgado J, Knobel H, Trenchs-Rodríguez M, Díez-Pérez A, Brown TT, García-Giralt N, Güerri-Fernández R. Inflammation status in HIV-positive individuals correlates with changes in bone tissue quality after initiation of ART. J Antimicrob Chemother 2019; 74(5): 1381-1388. IF 5.113. D1.

• Sorli L, Luque S, Li J, Campillo N, Danés M, Montero M, Segura C, Grau S, Horcajada JP. Colistin in the treatment of urinary tract infections caused by extremely drug-resistant Pseudomonas aeruginosa: dose is critical. J Infection 2019; 79(3): 253-261. IF 5.099. Q1.

• Luque S, Hope W, Campillo N, Muñoz-Bermúdez R, Sorli L, Barceló-Vidal J, González E, Álvarez-Lerma F, Masclans JR, Montero M, Horcajada JP, Grau S. Population pharmacokinetics of anidulafungin in critically ill patients. Antimicrob Agents Chemother 2019; 63(7): e00378-19. IF 4.715. Q1.


Inflammatory and Cardiovascular Disorders Infectious Pathology and Antimicrobials

https://www.imim.es/programesrecerca/inflamacio/en_antibioterapia.html?n=&any=2019&enviar.x=29&enviar.y=21&t=publicacions&g=37




• Estudio de la toxicidad ósea asociada al tratamiento antirretroviral por microindentación y el papel de los miRNA como biomarcadores de afectación ósea

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI16/01860)- Period: from 2017 to 2020- Principal investigator: Güerri Fernández, Roberto Carlos

• Análisis de la actividad de diferentes opciones terapéuticas frente a “clones de alto riesgo” de Pseudomonas aeruginosa extremadamente resistente (XDR) aisladas en hospitales españoles mediante modelos PK-PD mono y bicompartimentales (Hollow fiber)

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI16/00669)- Period: from 2017 to 2020- Principal investigator: Montero, María Milagro

• Impacto clínico y microbiológico de los nuevos antipseudomónicos ceftolozano-tazobactam y ceftazidima-avibactam en las infecciones por Pseudomonas aeruginosa extremadamente resistente

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI17/00251)- Period: from 2018 to 2020- Principal investigator: Horcajada Gallego, Juan Pablo

• Clinical and microbiological impact of the new antipseudomonal agents ceftolozane/tazobactam and ceftazidime/avibactam in infections caused by high-risk clones of extensively drug-resistant (XDR) Pseudomonas aeruginosa in Spain. Correlation with in vitro results using a Hollow Fiber dynamic PK/PD model

- Financing institution: Fundació La Marató de TV3 (201817-10)- Period: from 2019 to 2022- Principal investigator: Horcajada Gallego, Juan Pablo

• Estudio clínico y microbiológico sobre el impacto de la multirresistencia en la virulencia y en la respuesta del huésped a la infección por Pseudomonas aeruginosa

- Financing institution: SEIMC (201817-10)- Period: from 2019 to 2021- Principal investigator: Gómez-Zorrilla Martín, Silvia Inés

See all Projects

https://www.imim.es/programesrecerca/inflamacio/en_antibioterapia.html?t=projectes&g=37




• Red Española de Investigación en Patologías Infecciosas- Financing institution: Fondo de Investigación Sanitaria-ISCIII. Subprograma RETICS

(RD16/0016/0015)- Period: from 2017 to 2021- Principal investigator: Horcajada Gallego, Juan Pablo


• Ensayo clínico abierto, aleatorizado y multicéntrico para comparar la eficacia, seguridad y tolerabilidad de una pauta de tratamiento TAF/FTC/DRV/cobi vs. ABC/3TC/DTG en pacientes infectados por el VIH-1 naïve de tratamiento antirretroviral

- Protocol: Estudio SYMTRI- Sponsor: Asociación IRIS (Red de Investigación en Sida)- Budget: 2,066.1 €- Principal investigator: Knobel Freud, Hernando

• Estudio en fase III para evaluar el efecto de la pitavastatina para prevenir los acontecimientos cardiovasculares en personas con infección por VIH-1

- Protocol: Reprieve- Sponsor: Neat Id Foundation- Budget: 26,480 €- Principal investigator: Knobel Freud, Hernando

• Estudio aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis, en el que se evalúan la seguridad, la farmacocinética y el beneficio clínico de FLU-IGIV en pacientes hospitalizados con infección grave por el virus de la influenza A

- Protocol: IA-001- Sponsor: Emergent Biosolutions Canada Inc- Budget: 17,539.5 €- Principal investigator: Horcajada Gallego, Juan Pablo

• Ensayo clínico de fase IV-III, con asignación aleatoria, controlado, abierto y multicéntrico, con dos grupos paralelos, para evaluar la eficacia de la combinación de cloxacilina y fosfomicina versus cloxacilina en monoterapia en el tratamiento de la bacteriemia por staphylococcus aureus sensible a la meticilina

- Protocol: HUB-IDIBELL-SAFO-4.3.1- Sponsor: Dr. Miquel Pujol Rojo (Hospital Universitari de Bellvitge)- Principal investigator: Gómez-Zorrilla Martín, Silvia Inés



• Retrospective study to identify the incidence, risk factors and outcomes of prosthetic joint infection due to Staphylococcus aureus after primary knee or hip joint replacement

- Protocol: FIS-MET-2019-01- Sponsor: Fundacion Pública Andaluza para la Gestión de la Investigacion en Salud

de Sevilla- Budget: 4,400 €- Principal investigator: Horcajada Gallego, Juan Pablo

• Strategic Timing of AntiRetroviral Treatment (START Study)- Protocol: INSIGHT001: START-DAIDSID: 10619- Sponsor: University of Minnesota- Budget: 3,862 €- Principal investigator: Knobel Freud, Hernando

• Ceftolozano/tazobactam para el tratamiento de la bacteriemia por Pseudomonas aeruginosa multirresistente en pacientes neutropénicos con cáncer (estudio ZENITH)

- Protocol: CGG-CEF-2018-01- Sponsor: IDIBELL- Principal investigator: Montero, María Milagro

• A Phase 3, Multicenter, Randomized, Double-blind Study of the Efficacy and Safety of Rezafungin for Injection versus Intravenous Caspofungin Followed by Optional Oral Fluconazole Step-down in the Treatment of Subjects with Candidemia and/or Invasive Candidiasis (The ReSTORE Study)

- Protocol: CDIOI.IV.3.05 A3- Sponsor: Cidara Therapeutics Inc.- Budget: 37,755 €- Principal investigator: Horcajada Gallego, Juan Pablo

• Eficacia y tolerancia de 4 semanas de tedizolid en infección protésica articular tratadas con retirada del implante

- Protocol: PROTEDI- Sponsor: Fundació Clínic per a la Recerca Biomèdica- Principal investigator: Sorli Redó, María Luisa

Theses

• Balcells E. Normalització segons edat i sexe del component força de l’escala de Constant de valoració de la funció de l’espatlla. Universitat Autònoma de Barcelona

- Directors: Luís Puig Verdié; Daunis, J. - Date of defense: 18/09/2019



• Esteve-Palau E. Impacte clínic i econòmic de les infeccions urinàries per E. Coli Blee i de l’aplicació d’un programa d’optimització d’antimicrobians (PROA) en el seu abordatge terapèutic. Universitat Autònoma de Barcelona

- Directors: Horcajada Gallego, Juan Pablo; Grau Cerrato, Santiago- Date of defense: 14/01/2019

• Lerma E. Estudio del impacto de la infección por VIH en el metabolismo óseo. Universitat Autònoma de Barcelona

- Directors: Díez-Pérez A; Knobel Freud, Hernando- Date of defense: 03/06/2019

• Mari-Molina R. Cutibacterium acnes després de la preparació quirúrgica de les artroplàsties d’espatlla: de la pell als teixits profunds. Universitat Autònoma de Barcelona

- Directors: Torrens, C; Puig Verdié, Luís- Date of defense: 30/09/2019


• Curso Intensivo de Terapia Antimicrobiana “Dr. Drobnic”. Hospital del Mar, Barcelona, 25-29 March 2019.


• Juan Pablo Horcajada. Les infeccions incurables ja són aquí. Science Festival 2019. Barcelona, 27 October 2019.


The Research Group on Inflammatory and Neoplastic Dermatological Diseases is composed of dermatologists, biologists and immunologists, connecting the bedside with the bench, which is a clear example of translational research. The group includes two different lines of investigation:

• The study of inflammatory dermatological diseases, mainly psoriasis, urticaria and bullous diseases:

A) In psoriasis, we have developed a new in-vitro model which allows us to study the pathogenic mechanisms involved in early stages of the disease in different

Group LeaderRamon Maria Pujol Vallverdú

[email protected]

Members

Luis Gustavo Deza Vargas (Researcher)Ana María Giménez Arnau (Researcher)María Inmaculada Hernández Muñoz (Researcher)Gemma Martín Ezquerra (Researcher)Sònia Segura Tigell (Researcher)Laia Curto Barredo (PhD Student)Marta Ferran Farrés (PhD Student)Evelyn Andrades López (Technician)Mónica Hijós Rullo (Technician)Clara Ribas Llauradó (Technician)Sílvia Sánchez Serrano (Technician)


Inflammatory and Neoplastic Dermatological Diseases


Inflammatory and Cardiovascular Disorders Inflammatory and Neoplastic Dermatological Diseases

psoriasis phenotypes, consisting of the coculture of circulating CLA+ T cells (with cutaneous tropism), together with autologous epidermic cells from psoriatic patients, activated with Streptococcus pyogenes (SP) extract, a well-known psoriasis trigger. In addition, we focus on the characterization of T cell response in psoriasis.

B) In urticaria, the ongoing projects are related to the definition of clinical phenotypes of the diseases along with transcriptome analysis of severe chronic spontaneous urticaria (CSU) and cold urticaria, and the detection of potential biomarkers of clinical evolution and response to treatment.

C) In autoimmune bullous diseases, the studies focus on the role of the innate immune system in the pathogenetic mechanisms of acquired epidermolysis bullosa.

• Research into the pathogenetic mechanisms of progression and immunological response to nonmelanoma skin cancer. Our group also studies the link between inflammation and cutaneous squamous cell carcinoma (SCC). Our preliminary results show that metastatic SCC displays enhanced Polycomb levels (an epigenetic repressor family) and that Polycomb represses cytokine/chemokine expression in SCC cells. Our working hypothesis is that Polycomb repression of cytokine/chemokine expression in SCC blocks differentiation and function of the myeloid inflammatory component and favors a protumoral immune response.

Main Publications

• Maurer M, Giménez-Arnau AM, Sussman G, Metz M, Baker DR, Bauer A, Bernstein JA, Brehler R, Chu CY, Chung WH, Danilycheva I, Grattan C, Hébert J, Katelaris C, Makris M, Meshkova R, Savic S, Sinclair R, Sitz K, Staubach P, Wedi B, Löffler J, Barve A, Kobayashi K, Hua E, Severin T, Janocha R. Ligelizumab for Chronic Spontaneous Urticaria. New Engl J Med 2019; 381(14): 1321-1332. IF 70.67. D1.

• Deza G, March-Rodríguez A, Sánchez-Serrano S, Ribas-Llauradó C, Soto D, Pujol RM, Gimeno R, Giménez-Arnau AM. Relevance of the basophil high-affinity IgE receptor in chronic urticaria: Clinical experience from a tertiary care institution. J Allergy Clin Immunol Pract 2019; 7(5): 1619-1626.e1. IF 7.55. Q1.

• Wilkinson M, Gonçalo M, Aerts O, Badulici S, Bennike NH, Bruynzeel D, Dickel H, García-Abujeta JL, Giménez-Arnau AM, Hamman C, Isaksson M, Johansen JD, Mahler V, Niklasson B, Orton D, Pigatto P, Ponyai G, Rustemeyer T, Schuttelaar MLA, Spiewak R, Thyssen JP, Uter W. The European baseline series and recommended additions: 2019. Contact Dermatitis 2019; 80(1): 1-4. IF 5.504. D1.

• Balato A, Raimondo A, Arenberger P, Bruze M, Czarnecka-Operacz M, Johanssen JD, Gonçalo M, Ranki A, Uter W, Wilkinson M, Ayala F, John SM, Giménez-Arnau AM, Gollnick H. The role of the dermatologist in the immune-mediated/allergic diseases - position statement of the EADV task force on contact dermatitis, EADV task force on



occupational skin diseases, UEMS-EBDV subcommission allergology and European Dermatology Forum. J Eur Acad Dermatol Venereol 2019; 33(8): 1459-1464. IF 5.113. D1.

• García-Díez I, Hernández-Muñoz I, Hernández-Ruiz E, Nonell L, Puigdecanet E, Bódalo-Torruella M, Andrades E, Pujol RM, Toll A. Transcriptome and cytogenetic profiling analysis of matched in situ/invasive cutaneous squamous cell carcinomas from immunocompetent patients. Genes Chromosomes Cancer 2019 Mar; 58(3): 164-174. IF 3.44. D1.



• Regulación epigenética de la función inflamatoria del componente epitelial en la progresión metastática del carcinoma escamoso cutáneo (CEC)

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI15/00236)- Period: from 2016 to 2019- Principal investigator: Hernández Muñoz, María Inmaculada

• Caracterización de la respuesta immune frente a Streptococcus pyogenes a través de los linfocitos T CLA+ en la psoriasis guttata y en la psoriasis en placas

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI16/00532)- Period: from 2017 to 2020- Principal investigator: Pujol Vallverdú, Ramon Maria

• Inmunofenotipificación y caracterización genética de la urticaria crónica por contacto al frío o “urticaria a frigore”

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI17/00198)- Period: from 2018 to 2020- Principal investigator: Giménez Arnau, Ana María

• Estudio funcional del efecto de inhibición farmacológica en modelo in vivo murino de células primarias de síndrome de Sézary (linfoma cutáneo de células T)

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI18/00021)- Period: from 2019 to 2021- Principal investigator: Gallardo Hernández, Fernando

• Mecanismos epigenéticos implicados en la progresión metastática del carcinoma escamoso cutáneo (CEC): papel de la disqueratina y los RNAs no codificantes de pequeño tamaño

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI18/00065)- Period: from 2019 to 2021- Principal investigator: Hernández Muñoz, María Inmaculada

See all Projects

https://www.imim.es/programesrecerca/inflamacio/en_malatiesdermatol_giquesinflamat_ries.html?n=&any=2019&enviar.x=38&enviar.y=24&t=publicacions&g=33

https://www.imim.es/programesrecerca/inflamacio/en_malatiesdermatol_giquesinflamat_ries.html?t=projectes&g=33




• Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo, de 52 semanas de duración para demostrar la eficacia, seguridad y tolerabilidad de inyecciones subcutáneas de secukinumab con autoinyectores de 2 ml (300 mg) en pacientes adultos con psoriasis en placas de moderada a grave – MATURE

- Protocol: CAIN457A2325- Sponsor: Novartis Farmacéutica, S.A.- Budget: 15,680.01€- Principal investigator: Ferran Farrés, Marta

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis - BREEZE-AD7

- Protocol: I4V-MC-JAIY- Sponsor: Lilly, S.A.U.- Budget: 47,140 €- Principal investigator: Curto Barredo, Laia

• Estudio de búsqueda de dosis, doble ciego y controlado con placebo para evaluar la seguridad y eficacia de tezepelumab en monoterapia o en combinación con corticosteroides tópicos en la dermatitis atópica de moderada a grave

- Protocol: 20170755- Sponsor: Amgen, SA- Budget: 42,545 €- Principal investigator: Curto Barredo, Laia

• Estudio fase 2b, de búsqueda de dosis, multicéntrico, aleatorizado, doble ciego, controlado con placebo, para investigar la eficacia, seguridad y tolerabilidad de LOU064 en pacientes adultos con urticaria crónica espontánea inadecuadamente controlados con antihistamínicos H1

- Protocol: CLOU064A2201- Sponsor: Novartis Farmacéutica, S.A.- Budget: 22,000 €- Principal investigator: Giménez Arnau, Ana María

• A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis

- Protocol: M18-891- Sponsor: Abbvie Spain, S.L.U.- Budget: 53,895 €- Principal investigator: Pujol Vallverdú, Ramon Maria



• Estudio aleatorizado, doble ciego, controlado con placebo, multicéntrico para evaluar la eficacia y seguridad del inhibidor oral de BTK PRN1008 en el pénfigo moderado a grave

- Protocol: PRN1008-012- Sponsor: Principia Biopharma- Budget: 11,851.26 €- Principal investigator: Curto Barredo, Laia

• Estudio de fase 3, multicéntrico, doble ciego, en el que se evalúan la seguridad y la eficacia a largo plazo de baricitinib en pacientes adultos con dermatitis atópica

- Protocol: I4V-MC-JAHN- Sponsor: Lilly, S.A.U.- Budget: 85,670 €- Principal investigator: Curto Barredo, Laia

• Estudio de resultados sanitarios en la psoriasis (PSoHO): estudio observacional internacional de resultados sanitarios durante 3 años sobre el tratamiento biológico de la psoriasis en placas de moderada a grave

- Protocol: I1F-MC-B007- Sponsor: Eli Lilly and Company Limited- Budget: 13,370 €- Principal investigator: Ferran Farrés, Marta

• Un estudio en fase 2b/3 aleatorizado, con enmascaramiento doble, controlado con placebo, de intervalos de dosis, para investigar la eficacia y seguridad de PF-06651600 en sujetos adultos y adolescentes con alopecia areata (AA) con una pérdida de cabello en el cuero cabelludo del 50% o más

- Protocol: B7981015- Sponsor: Pfizer, Inc- Budget: 33,798.5 €- Principal investigator: Pujol Vallverdú, Ramon Maria

• Estudio de extensión multicéntrico y abierto para evaluar la seguridad y tolerabilidad a largo plazo de LOU064 en pacientes elegibles con urticaria crónica espontánea que hayan participado en estudios anteriores con LOU064

- Protocol: CLOU064A2201E1- Sponsor: Novartis Farmacéutica, S.A. - Budget: 31,825 €- Principal investigator: Giménez Arnau, Ana María



• Efectividad de la PUVA-terapia local en afecciones palmoplantares: estudio observacional, prospectivo y multicéntrico del Grupo Español de Fotobiología (GEF)

- Protocol: MAR-MET-2015-01- Sponsor: Rodríguez Granados, M. Teresa- Budget: No economic compensation- Principal investigator: Ferran Farrés, Marta

• A Multicenter, Long-Term Extension to Evaluate the Long-Term Safety and Maintenance of Treatment Effect of Mirikizumab in Patients with Moderate-to-Severe Plaque Psoriasis

- Protocol: I6T-MC-AMAH- Sponsor: Lilly, S.A.U.- Budget: 120,785.01 €- Principal investigator: Pujol Vallverdú, Ramon Maria

• An exploratory, multicenter, randomized, open-label with blind evaluation, active-controlled study to evaluate the safety and efficacy of Keramod® (imiquimod 50 mg/g, Gel) compared with Aldara® (imiquimod 50 mg/g, Cream) for the treatment of actinic keratosis in adults

- Protocol: OJ-KDC01- Sponsor: Laboratorios Ojer Pharma, S.L.- Budget: 57,052 €- Principal investigator: Segura Tigell, Sònia

• Estudio observacional para evaluar la efectividad descriptiva en el mundo real en pacientes con psoriasis en placa de moderada a grave tratados con brodalumab

- Protocol: LEO-BRO-2019-01 (NIS-KYNTHEUM-1466)- Sponsor: Leo Pharma- Budget: 15,286.2 €- Principal investigator: Ferran Farrés, Marta

• Estudio de extensión de retirada, aleatorizado, doble ciego y multicéntrico para demostrar la eficacia, seguridad y tolerabilidad a largo plazo de secukinumab subcutáneo en pacientes con hidradenitis supurativa de moderada a grave

- Protocol: CAIN457M2301E1- Sponsor: Novartis Farmacéutica S.A. - Budget: 25,170 €- Principal investigator: Martín Ezquerra, Gemma


• Estudio de fase III, abierto, multicéntrico, a largo plazo, para investigar la seguridad y la eficacia de PF-06651600 en participantes adultos y adolescentes con alopecia areata

- Protocol: B7981032 - Sponsor: Pfizer INC- Budget: 38,336.1 €- Principal investigator: Pujol Vallverdú, Ramon Maria

• Estudio retrospectivo multicéntrico de práctica clínica habitual en paciente con psoriasis moderada a grave tratados con Guselkumab

- Protocol: JAN-GUS-2019-02 / CNTO1959PSO4010- Sponsor: Janssen-Cilag- Budget: 1,800 €- Principal investigator: Pujol Vallverdú, Ramon Maria

• Estudio aleatorizado, doble ciego, multicéntrico que evalúa la eficacia a corto (16 semanas) y largo plazo (hasta un año), la seguridad y la tolerabilidad de 2 regímenes de dosis de secukinumab subcutáneo, en pacientes adultos con hidradenitis supurativa de moderada a severa (SUNRISE)

- Protocol: CAIN457M2302- Sponsor: Novartis Farmacéutica S.A. - Budget: 46,400 €- Principal investigator: Martín Ezquerra, Gemma; Ferran Farrés, Marta

Awards

• M. Ferran, E. Ruiz-Romeu, C. de Jesús, A. Celada, R.M. Pujol, L.F. Santamaria-Babí. La inhibición de PD-L1 da lugar a una respuesta IL-17 en los cocultivos de linfocitos T CLA+ con células epidérmicas activados por S. pyogenes en psoriasis. Reunión del Grupo de Psoriasis de la Academia Española de Dermatología y Venereología. Madrid, January 20th 2019. Award to best poster presentation.



Group LeaderJulio Pascual Santos

[email protected]

Members

Carlos Enrique Arias Cabrales (Researcher)Clara Barrios Barrera (Researcher)Marta Crespo Barrio (Researcher)Javier Gimeno Beltrán (Researcher)Anna Oliveras Serrano (Researcher)María José Pérez Sáez (Researcher)Dàlia Raïch Regué (Researcher)María Dolores Redondo Pachón (Researcher)Marta Riera Oliva (Researcher)Eva Rodríguez García (Researcher)Laia Sans Atxer (Researcher)Susana Vázquez González (Researcher)Carla Cristina Burballa Tàrrega (PhD Student)Sílvia Collado Nieto (PhD Student)Laura Llinàs Mallol (PhD Student)Vanesa Palau González (PhD Student)Sara Álvarez Morales (Technician)David Benito Guasch (Technician)Anna Buxeda Porras (Technician)Anna Faura Vendrell (Technician)Montserrat Folgueiras López (Technician)Adriana Sierra Ochoa (Technician)Maria Vera Casanova (Techncian)


Kidney DiseaseRESEARCH GROUP


Inflammatory and Cardiovascular Disorders Kidney Disease

The Kidney Research Group (GREN) at IMIM belongs to the Nephrology Department of Parc de Salut Mar, Barcelona, Spain. The Nephrology Department covers structured assistance to the renal patient in four areas: clinical nephrology, kidney transplantation, chronic kidney disease and hypertension-cardiovascular risk. The department has made a particular effort in the area of kidney transplantation, covering all transplant modalities (deceased donor, living donor, sensitized patients, ABO-incompatible, etc).

GREN also has a basic-translational lab, in which a number of biologists (pre and postdoc) work together with nephrology physicians to achieve research objectives in different specialized areas. It belongs to the Red de Investigación Renal (renal research network - REDinREN) and is recognized by AGAUR.

The group aims to clarify mechanisms involved in the onset and progression of kidney diseases through preclinical research into in vivo and in vitro models. This makes it possible to study the molecular mechanisms involved, and will thus help us to identify the treatment targets and new strategies against kidney disease.

We also aim to study new treatment targets and strategies in depth by performing controlled clinical trials and observational projects of great interest, while securing all levels of possible commitment: promoters, main researchers, collaboration in multicenter projects and own projects.

Our research focuses mainly on three research areas: diabetic kidney disease and early markers of chronic kidney disease (C. Barrios PI16/00620), resistant hypertension (A. Oliveras EC11-426 and PI16/01356), new pathogenetic and therapeutic targets in the field of kidney transplantation (J. Pascual and M. Crespo PI13/00598, PI16/00617) and kidney transplantation in old and frail patients (J. Pascual, PI19/0037).

Main Publications

• Berger SP, Sommerer C, Witzke O, Tedesco H, Chadban S, Mulgaonkar S, Qazi Y, de Fijter JW, Oppenheimer F, Cruzado JM, Watarai Y, Massari P, Legendre C, Citterio F, Henry M, Srinivas TR, Vincenti F, Gutiérrez MPH, Martí AM, Bernhardt P, Pascual J; TRANSFORM investigators. Two-year outcomes in de novo renal transplant recipients receiving everolimus-facilitated calcineurin inhibitor reduction regimen from the TRANSFORM study. Am J Transplant 2019; 19(11):3018-3034. IF 7.163. D1.

• Montero N, Quero M, Melilli E, Pérez-Sáez MJ, Redondo-Pachón D, Bestard O, Crespo M, Cruzado JM, Pascual J. Mammalian Target of Rapamycin Inhibitors Combined With Calcineurin Inhibitors as Initial Immunosuppression in Renal Transplantation: A Meta-analysis. Transplantation 2019; 103(10):2031-2056. IF 4.743. D1.

• Llinàs-Mallol L, Redondo-Pachón D, Pérez-Sáez MJ, Raïch-Regué D, Mir M, Yélamos J, López-Botet M, Pascual J, Crespo M. Peripheral blood lymphocyte subsets change after steroid withdrawal in renal allograft recipients: a prospective study. Sci Rep 2019; 9(1):7453. IF 4.011. Q1.



• Palau V, Pascual J, Soler MJ, Riera M. Role of ADAM17 in kidney disease. Am J Physiol Renal Physiol 2019; 317(2):F333-F342- IF 3.323. Q1.

• Buxeda A, Redondo-Pachón D, Pérez-Sáez MJ, Bartolomé Á, Mir M, Pascual-Dapena A, Sans A, Duran X, Crespo M, Pascual J. Gender differences in cancer risk after kidney transplantation. Oncotarget 2019; 10(33):3114-3128.



• Adherencia terapéutica en Hipertensión Arterial no controlada: detección selectiva y eficacia y efectividad de un programa para mejorar el cumplimiento (Athan)

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI16/01356) - Period: from 2017 to 2019- Principal investigator: Oliveras Serrano, Anna

• Anticuerpos HLA y no HLA en el rechazo del trasplante renal y mecanismos de lesión- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI16/00617)- Period: from 2017 to 2020- Principal investigator: Pascual Santos, Julio

• Estudio de metabolómica y glicómica para la identificación de biomarcadores de función y daño renal en la diabetes mellitus tipo 2

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI16/00620)- Period: from 2017 to 2021- Principal investigator: Barrios Barrera, Clara

• Estudi multicèntric, aleatoritzat per avaluar l’eficàcia de la individualització del risc immunològic basat en biomarcadors selectius (Disparitat d’Eplets HLA i Elispot IFN-Y), per optimitzar el tractament immunosupressor en pacients trasplantats renals de donant viu (BIOIMMUN)

- Financing institution: Departament de Salut de la Generalitat de Catalunya (SLT002/16/00183)

- Period: from 2017 to 2019- Principal investigator: Crespo Barrio, Marta

See all Projects

https://www.imim.es/programesrecerca/inflamacio/en_nefropaties.html?n=&any=2019&enviar.x=43&enviar.y=19&t=publicacions&g=11

https://www.imim.es/programesrecerca/inflamacio/en_nefropaties.html?t=projectes&g=11




• Red de Investigación Renal (REDINREN)- Financing institution: Fondo de Investigación Sanitaria-ISCIII. Subprograma RETICS. RD16/0009/0013- Period: from 2017 to 2022- Principal investigator: Pascual Santos, Julio


• Estudio multicéntrico, aleatorizado, doble ciego, controlado con placebo en dos etapas para caracterizar la eficacia, seguridad, tolerabilidad y farmacocinética de GZ/SAR402671 en pacientes con Enfermedad Renal Poliquística Autosómica Dominante (ERPAD) en riesgo de progresión rápida

- Protocol: EFC15392- Sponsor: Sanofi Aventis, SA- Budget: 182,475 €- Principal investigator: Sans Atxer, Laia

• A Phase 3b, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of TRC101 in Delaying Chronic Kidney Disease Progression in Subjects with Metabolic Acidosis

- Protocol: TRCA-303 (VALOR-CKD)- Sponsor: TRICIDA- Budget: 37,015 €- Principal investigator: Collado Nieto, Silvia

• Efecto de semaglutida en comparación con placebo sobre la progresión de la insuficiencia renal en sujetos con diabetes de tipo 2 y nefropatía crónica

- Protocol: NN9535-4321- Sponsor: Novo Nordisk A/S- Budget: 95,333.26 €- Principal investigator: Pascual Santos, Julio

• A Pivotal Phase 3 Trial to Evaluate the Safety and Efficacy of Clazakizumab for the Treatment of Chronic Active Antibody-Mediated Rejection in Kidney Transplant Recipients

- Protocol: VKTX01- Sponsor: Vitaeris- Budget: 166,956.2 €- Principal investigator: Crespo Barrio, Marta



• Semaglutide cardiovascular outcomes trial in patients with type 2 diabetes (SOUL)- Protocol: EX9924-4473 (SOUL)- Sponsor: Novo Nordisk Pharma S.A- Budget: 153,000 €- Principal investigator: Pascual Santos, Julio

• Ensayo en Fase III Sobre la Eficacia y Seguridad del Metilbardoxolona en Pacientes con Enfermedad Poliquística Renal Autosómica Dominante

- Protocol: 402-C-1808- Sponsor: REATA- Budget: 42,515.01 €- Principal investigator: Sans Atxer, Laia

Theses

• Otero S. Marcadores alternativos de daño renal asociado a la diabetes. Universitat Autònoma de Barcelona

- Directors: Barrios Barrera, Clara; Pascual Santos, Julio - Date of defense: 25/04/2019

Awards

• Marta Crespo. Premi a l’excel·lència investigadora del COMB. December 2019.

• M. Fernández, Y Martínez, E. Junyent, S. Collado. Resultados de la implantación de la consulta de ayuda a la decisión en la elección de terapia renal sustitutiva. XLIV Congreso Nacional de la SEDEN. Premio SEDEN Enfermedad Renal Crónica Avanzada. Coruña, 8-10 October 2019.

• ara Núñez, Anna Buxeda, Laia Sans, Susana Vázquez, Julio Pascual, Anna Oliveras. XXVI Reunió de la Societat Catalana d’Hipertensió Arterial – XXXII Jornades Catalanes sobre Hipertensió Arterial. XX Award for best clinical case. 11 December 2019.

• P. Fernández-Llama, P. Armario, À. de la Sierra, A. Oliveras. Research award in Nephrology, 2019. Sociedad Española de Nefrología. September 2019.

Appointments

• Marta Crespo. Member of the board of the working group DESCARTES (Developing Education Science and Care for Renal Transplantation in European States) of the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA). 2019




• Marta Crespo, María José Pérez Sáez. Coordinators and teachers. Curso de Trasplante para Residentes de Nefrología. Sociedad Española de Nefrología (SEN). Alcalá de Henares, 14-16 November 2019.

• Marta Crespo, Dolores Redondo. Coordinators. Workshop HLA. XLIX Congreso de la Sociedad Española de Nefrología. A Coruña, 5-8 October 2019.

• María José Pérez-Sáez. Outcomes of frail patients after kidney transplantation. 56th EDTA Congress. Budapest, Hungary. 13-16 June 2019.

• María José Pérez-Sáez. I Curso de Trasplante para enfermeras de Nefrología. Barcelona, 21-28 March 2019.


• Marta Crespo. Jornada Trasplante Renal de Donante Vivo. Hospital del Mar. May 2019.

• Marta Crespo. Què representa per a l’investigador posar en marxa el seu projecte de recerca gràcies a la suma d’esforços dels donants a La Marató, la primera iniciativa solidària del país? Masterclass de La Marató de TV3. Campus Hospital del Mar. 9 April 2019.


Our research is based on the use of patients from clinical settings, animal models of disease, and in vitro primary cultures. We use all kinds of biochemical and cellular and molecular biology techniques (RT-PCR, immunoblotting, immunohistochemistry, 2-D electrophoresis, proteomics analysis, ELISA, activity assays, mitochondrial respiration, flow cytometry, etc.) in order to explore the target mechanisms of our research.

The most relevant achievements of our research have been the following: demonstrating that oxidative and nitrosative stress, ubiquitin-proteasome system, NF-kB and FoxO signaling, alterations of epigenetic regulation, and loss of muscle-specific proteins are important players in COPD- and lung cancer-associated cachexia, whereas muscle inflammation does not play a role in this process.

Group LeaderEsther Barreiro Portela

[email protected]

Members

Víctor Curull Serrano (Researcher)Marisol Domínguez Álvarez (Researcher)María Guitart de la Rosa (Researcher)Lara Pijuan Andújar (Researcher)Alberto Rodríguez Fuster (Researcher)Albert Sánchez Font (Researcher)Maria Pérez Peiró (PhD Student)


Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer


Inflammatory and Cardiovascular Disorders Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer

Moreover, in the last five years, we have started a new avenue of research focusing on the underlying biology that accounts for the greater susceptibility of patients with chronic respiratory diseases (e.g. COPD) to developing lung tumors. We have demonstrated that increased oxidative stress, inflammatory cytokines and disruption of epigenetic regulation are involved in the greater susceptibility of patients with COPD to developing lung cancer.

Finally, we are currently undertaking a new line of research in muscle regeneration. Our first relevant achievement in this area has been the demonstration that there is a decline in the number of satellite cells (SC) following hindlimb immobilization in mice together with an upregulation of markers of SC activation, suggesting that fusion to existing myofibers takes place during unloading. Muscle recovery induces a significant rise in muscle precursor cells and regeneration events along with reduced SC-activation expression markers and a concomitant rise in terminal muscle differentiation expression.

Main Publications

• Tang J, Ramis-Cabrer D, Xuejie W, Barreiro E. Immunotherapy with Monoclonal Antibodies in Lung Cancer of Mice: Oxidative Stress and Other Biological Events. Cancers 2019; 11(9): E1301. IF 6.162. Q1.

• Barreiro E, Wang X, Tang J. COPD: preclinical models and emerging therapeutic targets. Expert Opin Ther Targets 2019; 23(10): 829-838. IF 4.621. Q1.

• Barreiro E, Salazar-Degracia A, Sancho A, Gea J. Endoplasmic reticulum stress and unfolded protein response profile in quadriceps of sarcopenic patients with respiratory diseases. J Cell Physiol 2019; 234(7): 11315-11329. IF 4.522. Q1.

• Busquets S, Pérez-Peiró M, Salazar-Degracia A, Argilés JM, Serpe R, Rojano-Toimil A, López-Soriano FJ, Barreiro E. Differential structural features in soleus and gastrocnemius of carnitine-treated cancer cachectic rats. J Cell Physiol 2020; 235(1): 526-537. IF 4.522. Q1.

• Salazar-Degracia A, Granado-Martínez P, Millán-Sánchez A, Tang J, Pons-Carreto A, Barreiro E. Reduced lung cancer burden by selective immunomodulators elicits improvements in muscle proteolysis and strength in cachectic mice. J Cell Physiol 2019; 234(10): 18041-18052. IF 4.522. Q1.


https://www.imim.es/programesrecerca/inflamacio/en_urmar.html?n=&any=2019&enviar.x=24&enviar.y=16&t=publicacions&g=86




• Papel del estrés del retículo endoplásmico y PARP en el potencial regenerativo muscular en la sarcopenia asociada a la EPOC y la caquexia cancerosa: implicaciones terapéuticas

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI18/00075)- Period: from 2019 to 2021- Principal investigator: Barreiro Portela, Esther

See all Projects


• Centro de Investigación en Red de Enfermedades Respiratorias (CIBERES) - Financing institution: Fondo de Investigación Sanitaria. Subprograma CIBER

CB06/06/0043- Period: from 2006 to 2020- Collaborating investigator: Barreiro Portela, Esther- Principal investigator: Gea Guiral, Joaquim


• Heterogeneidad en la susceptibilidad a la infección en las bronquiectasias: Interacción huésped-microbioma y su valor predictivo en la práctica clínica. Proyecto BronchI-Omics

- Protocol: BronchI-Omics- Sponsor: Fundació Institut d’Investigació en Ciències de la Salut Germans Trias i

Pujol- Principal investigator: Barreiro Portela, Esther

Theses

• Anna Salazar Degracia. Mechanisms of muscle wasting in cachexia models: therapeutic implications. Universitat Pompeu Fabra

- Director: Barreiro Portela, Esther- Date of defense: 15/04/2019

• Daniel Ramis Cabré. From chronic obstructive pulmonary disease to lung cancer: an immunologic approach. Universitat Pompeu Fabra

- Director: Barreiro Portela, Esther- Date of defense: 11/07/2019

https://www.imim.es/programesrecerca/inflamacio/en_urmar.html?t=projectes&g=86



Awards

• L Mañas-García, J Deschevrel, M Guitart, A Penedo, E Barreiro. Contribution of prolonged immobilization and lung cancer cachexia to muscle mass loss in mice: Implications to the clinics in hospitalized patients. 3a Jornada de Recerca Bàsica en Pneumologia, XXXVII Diada Pneumològica. Terrassa, Barcelona, April 2019. Award for the best communication.

• J Tang, D Ramis Cabrer, V Curull Serrano, M Mateu-Jimenéz, L Pijuan, A Rodríguez-Fuster, R Aguiló Espases, E Barreiro. Immune profile and survival in lung cancer patients: influence of underlying COPD. 11 Jornadas de Formación del CIBERES. Madrid, October 2019. Award for the best communication.

Appointments

• Member of the Planning Committee for the ATS Assembly on ATS Respiratory Structure and Function (RSF), American Thoracic Society International Conference, USA. From May 2018.

• Member of the Steering Committee of the Asociación de Médicos Gallegos (ASOMEGA), Spain. From May 2018.

• Member of the Gender Policy Committee, Department of Experimental Sciences and Health, Universitat Pompeu Fabra. Barcelona. From June 2018.


• Laura Mañas, María Guitart. Visit to the Laboratory of the Research Group of Muscle Wasting and Cachexia in Chronic Respiratory Diseases and Lung Cancer. Open Day of the Parc de Recerca Biomèdica de Barcelona (PRBB), 5 October 2019.


Our research focuses on the study of musculoskeletal disorders and the underlying mechanisms of bone pathophysiology. The group covers three main areas of research: genetics, epidemiology, and bone quality.

In the genetics field, we are exploring the genetic basis of bone disorders for both complex diseases such as osteoporosis and rare disorders such as monogenic skeletal dysplasias. In this line, we are active members of the GEMSTONE, a European COST action for the study of the Genomics of MusculoSkeletal traits.

At population level, we are working in the epidemiology of bone outcomes using several cohorts: BARCOS, SIDIAP and B-ABLE, currently involved in ongoing studies related to bone health and frailty. The BARCOS cohort also belongs to the international GEFOS/GENOMOS consortium, which has performed several genome-wide studies and metanalyses. B-ABLE is a cohort of postmenopausal women with early breast cancer

Group LeaderFrancesc Xavier Nogués Solan

[email protected]

Members

Adolf Díez Pérez (Researcher)Leonardo Mellibovski Saidler (Researcher)Guillem Saló Bru (Researcher)Isabel Aymar Fábrega (Technician)Carme Giménez Argente (Technician)Abora Rial Villavecchia (Technician)Carme Sánchez Galiano (Research Assistant)


Musculoskeletal ResearchRESEARCH GROUP


Inflammatory and Cardiovascular Disorders Musculoskeletal Research

treated with aromatase inhibitors. SIDIAP is a database that provides anonymized clinical information as coded by primary care practitioners in Catalonia, covering more than 7 million patients. Moreover, we started a new frailty cohort (CohorFES), involving a number of Spanish centres in CIBERFES with the aim of finding trajectories to explain the worsening process of frailty.

Our research also encompasses a number of diseases and therapies that affect bone metabolism as a secondary outcome. These include HIV infection and antiretroviral therapies, atypical fractures due to bisphosphonate treatment and other diseases with bone involvement. Our group is a leading research group in the development of a novel, hand-held Reference Point Indentation (RPI) instrument, Osteoprobe®, which measures bone quality. Finally, our group is also working on the design of biomaterials and scaffolds for promoting the biointegration of implants in osseous and soft tissues.

Main Publications

• Díez-Pérez A, Marín F, Eriksen EF, Kendler DL, Krege JH, Delgado-Rodríguez M. Effects of teriparatide on hip and upper limb fractures in patients with osteoporosis: A systematic review and meta-analysis. Bone. 2019; 120: 1-8. IF 4.36. Q1.

• Pineda-Moncusí M, Servitja S, Tusquets I, Díez-Pérez A, Rial A, Cos ML, Campodarve I, Rodríguez-Morera J, García-Giralt N, Nogués X. Assessment of early therapy discontinuation and health-related quality of life in breast cancer patients treated with aromatase inhibitors: B-ABLE cohort study. Breast Cancer Res Treat. 2019; 177(1): 53-60. IF 3.471. Q2.

• Prieto-Alhambra D, Moral-Cuesta D, Palmer A, Aguado-Maestro I, Bardají MFB, Brañas F, Bueno GA, Caeiro-Rey JR, Cano IA, Barres-Carsi M, Delgado LG, Salomó-Domènech M, Etxebarria-Foronda I, Ferrer BL, Mills S, Herrando LE, Mifsut D, Evangelista LDR, Nogués X, Pérez-Coto I, Blasco JM, Martín-Hernández C, Kessel H, Serra JT, Solis JR, Suau OT, Vaquero-Cervino E, Hernández CP, Mañas LR, Herrera A, Díez-Pérez A. The impact of hip fracture on health-related quality of life and activities of daily living: the SPARE-HIP prospective cohort study. Arch Osteoporos. 2019; 14(1): 56. IF 2.469. Q2.

• Díez-Pérez A, Brandi ML, Al-Daghri N, Branco JC, Bruyère O, Cavalli L, Cooper C, Cortet B, Dawson-Hughes B, Dimai HP, Gonnelli S, Hadji P, Halbout P, Kaufman JM, Kurth A, Locquet M, Maggi S, Matijevic R, Reginster JY, Rizzoli R, Thierry T. Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art-outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Aging Clin Exp Res. 2019; 31(10): 1375-1389. IF 2.331. Q3.


https://www.imim.es/programesrecerca/inflamacio/en_estudigen_ticosteoporosi.html?n=&any=2019&enviar.x=25&enviar.y=19&t=publicacions&g=17




• Análisis objetivo mediante geolocalización del perímetro de la marcha en pacientes con estenosis del canal lumbar

- Financing institution: Sociedad para el Estudio de las Enfermedades del Raquis (GEER)

- Period: from 2018 to 2020- Principal investigator: Saló Bru, Guillem

• Estudio para la mejora de la calidad de vida en mujeres con cáncer de mama tratadas con inhibidores de aromatasa: cohorte B-ABLE

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI16/00818)- Period: from 2017 to 2020- Principal investigator: Nogués Solan, Francesc Xavier

See all Projects


• CIBER Frailty and Healthy Aging (CIBERFES)- Financing institution: Fondo de Investigación Sanitaria-ISCIII. CIBER

(CB16/10/00245)- Period: from 2017 to 2020- Principal investigator: Nogués Solan, Francesc Xavier

• GEnomics of MusculoSkeletal traits TranslatiOnal Network (GEMSTONE)- Financing institution: European COST action CA18139- Period: from 2019 to 2023- Principal investigator: Rivadeneira, Fernando

• European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO)

- Financing institution: European working group- Period: from 2019 to 2023- Principal investigator: Rivadeneira, Fernando

https://www.imim.es/programesrecerca/inflamacio/en_estudigen_ticosteoporosi.html?t=projectes&g=17




• Estudio de fases I/III integradas, aleatorizado, en doble ciego y multicéntrico, en mujeres posmenopáusicas con osteoporosis, comparativo de la farmacocinética, farmacodinamia, eficacia, seguridad e inmunogenia de GP2411 (producto biológico propuesto similar al denosumab) frente a Prolia® (producto autorizado en la UE)

- Protocol: CGP24112301- Sponsor: HEXAL- Budget: 88,425.6 €- Principal investigator: Nogués Solan, Francesc Xavier

• Prospective study for the detection of patients with X-Linked Hypophosphatemia (XLH) and other FGF23-mediated Hypophosphatemic genetic disorders in ambulatory care and Hospital outpatient clinic settings: The Barcelona Hypophosphatemia Study

- Sponsor: Kyowa Kirin Farmaceutica SLU- Budget: 84,200 €- Principal investigator: Nogués Solan, Francesc Xavier

Theses

• Lerma E. Estudio del impacto de la infección por VIH en el metabolismo óseo. Universitat Autònoma de Barcelona

- Directors: Díez Pérez, Adolf; Knobel H. - Date of defense: 03/06/2019

• Taymouri F. Reference data for bone material strength index (BMSI) measured by impact microindentation. Universitat Autònoma de Barcelona

- Directors: Díez Pérez, Adolf; Nogués Solan, Francesc Xavier- Date of defense: 08/02/2019

Appointments

• Francesc Xavier Nogués Solan. Director of the Inflammatory and Cardiovascular Disorders Programme. IMIM. 28/05/2019.


• Xavier Nogués, Adolfo Díez Pérez, Diana Ovejero. Impact microindentation training seminars. IMIM; November 2019.



• Xavier Nogués. Metástasis óseas de tumores sólidos. Fisiopatología de las metástasis óseas. Hospital del Mar, 12-13 September 2019.

• Xavier Nogués; Natalia Garcia Giralt. Organizing committee. SEIOMM Congress. Girona, 17-19 October 2019.


• Natalia Garcia Giralt, Xavier Nogués. Guided visit to IMIM for high school students from Institut Lluís Peguera. 5 February 2019.


Our ongoing research is focused on the role played by proinflammatory cytokines as a signaling molecules in the repairing-remodeling processes in muscles of patients with different processes with a relevant systemic inflammatory component, which share muscle dysfunction and/or loss of muscle mass. The strategic outcome is to identify potential molecular targets of therapies against muscle dysfunction and muscle cachexia. Our research is mainly addressed to lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and lung cancer, but also muscle problems in aging, fibromyalgia and scoliosis and includes clinical assessment, in vivo and in vitro physiological studies, and molecular biology procedures.

Group LeaderJoaquim Gea Guiral

[email protected]

Members

Pilar Ausín Herrero (Researcher)Carme Casadevall Fusté (Researcher)Antoni Ferrer Monreal (Researcher)Juana María Martínez Llorens (Researcher)Sergi Pascual Guardia (Researcher)Diego Agustín Rodríguez Chiaradia (Researcher)Ana Balañá Corberó (PhD Student)Eva Balcells Vilarnau (PhD Student)Roberto Chalela Rengifo (PhD Student)Mireia Admetlló Papiol (Technician)Lucilla Piccari (Technician)


Myogenesis, Inflammation & Muscle Function


More recently, we have initiated a line for the identification of molecular markers of different circumstances present in COPD patients (e.g. gravity, activity, comorbidities, systemic manifestations), using both conventional and ‘omics’ methodologies (transcriptomics, proteomics and metabolomics).

Main Publications

• Marín-Corral J, Dot I, Boguña M, Cecchini L, Zapatero A, Gracia MP, Pascual-Guardia S, Vilà C, Castellví A, Pérez-Terán P, Gea J, Masclans JR. Structural differences in the diaphragm of patients following controlled vs assisted and spontaneous mechanical ventilation. Intensive Care Med 2019; 45(4): 488-500. IF 18.967. D1.

• Chalela R, Bellosillo B, Curull V, Longarón R, Pascual-Guardia S, Badenes-Bonet D, Arriola E, Sánchez-Font A, Pijuan L, Gea J. EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma. J Clin Med 2019; 8(4): 529. IF 5.688. D1.

• Gea J, Pascual S, Castro-Acosta A, Hernández-Carcereny C, Castelo R, Márquez-Martín E, Montón C, Palou A, Faner R, Furlong LI, Seijo L, Sanz F, Torà M, Vilaplana C, Casadevall C, López-Campos JL, Monsó E, Peces-Barba G, Cosío BG, Agustí A; on behalf of the group BIOMEPOC. The BIOMEPOC Project: Personalized Biomarkers and Clinical Profiles in Chronic Obstructive Pulmonary Disease. Arch Bronconeumol 2019; 55(2): 93-99. IF 4.214. Q1.

• Barreiro E, Salazar-Degracia A, Sancho-Muñoz A, Aguiló R, Rodríguez-Fuster A, Gea J. Endoplasmic reticulum stress and unfolded protein response in diaphragm muscle dysfunction of patients with stable chronic obstructive pulmonary disease. J Appl Physiol 2019; 126(6): 1572-1586. IF 3.140. Q1.

• Barreiro E, Sancho-Muñoz A, Puig-Vilanova E, Salazar-Degracia A, Pascual-Guardia S, Casadevall C, Gea J. Differences in micro-RNA expression profile between vastus lateralis samples and myotubes in COPD cachexia. J Appl Physiol 2019 F; 126(2): 403-412. IF 3.140. Q1.



• Biomarcadores y perfiles clínicos personalizados en la Enfermedad Pulmonar Obstructiva Crónica

- Financing institution: Ministerio de Economía y Competitividad. Instituto de Salud Carlos III (SAF2014-54371-R)

- Period: from 2015 to 2019- Principal investigator: Gea Guiral, Joaquim

Inflammatory and Cardiovascular Disorders Myogenesis, Inflammation & Muscle Function

https://www.imim.es/programesrecerca/inflamacio/en_miogenesi.html?n=&any=2019&enviar.x=54&enviar.y=18&t=publicacions&g=31



• Deficiencia de hierro en pacientes con EPOC: Impacto de la reposición con hierro. FACE study (Ferinject Assessment in patients with COPD and iron deficiency to improve Exercise tolerance)

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI17/00649)- Period: from 2018 to 2020- Principal investigator: Rodríguez Chiaradia, Diego Agustín

See all Projects


• CIBER in Respiratory Diseases (CIBERES). Stable funding from the Spanish network of excellence in respiratory diseases

- Financing institution: Instituto de Salud Carlos III (CB06 / 06/0043)- Period: from 2016 to 2019

• MERMAIDS (Platform foR European Preparedness Against (Re)emerging Epidemics, PREPARE)

- Financing institution: European Commission. Oxford University (coordinating center). Ref: 2014-602525.

- Period: from 2017 to 2022


• Impacto de un programa de asistencia al paciente (PAP) en la persistencia al tratamiento con pirfenidona en pacientes con fibrosis pulmonar idiopática

- Register: ML40261- Principal investigator: Balcells Vilarnau, Eva

Appointments

• Joaquim Gea Guiral. President of the Comité de Grados Universitarios of the Sociedad Española de Neumología y Cirugía Torácica (SEPAR)

• Joaquim Gea Guiral. President of the Barcelona Respiratory Network Foundation

• Joaquim Gea Guiral. Member of the Advisory Board GlaxoSmithKline

• Joaquim Gea Guiral. Member of the Advisory Board AstraZeneca

• Joaquim Gea Guiral. Member of the Advisory Board Boehringer Ingelheim

• Joaquim Gea Guiral. Member of the Working Group to prepare the ERS statement on respiratory muscle testing at rest and during exercises of the European Respiratory Society (ERS)

https://www.imim.es/programesrecerca/inflamacio/en_miogenesi.html?t=projectes&g=31



• Joaquim Gea Guiral. Member of the Management Council of the European Board for Accreditation on Pneumology (EBAP)

• Joaquim Gea Guiral. Member of the Working Group for the improvement of the degree studies in Medicine of the Consell Interuniversitari de Catalunya (CIC), Generalitat de Catalunya

• Joaquim Gea Guiral. Member of the Working Group for the New Studies Plan of the Universitat Pompeu Fabra Medicine degree (PSMAR-UPF).


• Visit to the Laboratory of the Research Group of Myogenesis, Inflammation & Muscle Function. Open Day of the Parc de Recerca Biomèdica de Barcelona (PRBB), 5 October 2019.

• Juana María Martínez Llorens. Atenció Multidisciplinària a l’ELA. IV Jornada sobre ELA per a pacients, familiars i cuidadors. 3 May 2019.

• Anna Balañá. Workshop Maneig de secrecions respiratòries. IV Jornada sobre ELA per a pacients, familiars i cuidadors. 3 May 2019.


The Neuroimmunology Group was created in 2018 after initially being developed within the IMIM’s Immunity and Infection group. The group studies alterations of the immune system in neurological diseases using a translational approach centered on the patient’s clinical features. The Neuroimmunology Group is particularly interested in multiple sclerosis (MS) as a paradigmatic illness within the autoimmune pathologies of the central nervous system.

The group’s current areas of research focus on the following:

• The study of chronic herpes virus infections in MS (Epstein-Barr virus, Cytomegalovirus) and their imprint on the Natural Killer (NK) cell compartment, evaluating the potential development of biomarker predictors of activity and progression.

Group LeaderJose Enrique Martínez

Rodríguez

[email protected]

Elvira Munteis Olivas (Researcher) Mireia Llop Trujillano (Technician)Antia Moreira Villanueva (Technician)Andrea Vera Barrón (Technician)


NeuroimmunologyRESEARCH GROUP


• The immunophenotypic and functional analysis of adaptive NK cell populations and their role in the immunopathology of MS.

• Phenotypic and functional study of subpopulations of T and B lymphocytes in the peripheral blood of MS patients, evaluating their relationship with clinical characteristics and treatments that modify the clinical course of the disease.

• The immunology of neuromuscular disorders, with special interest in patients with myasthenia gravis.

The group currently receives funding from the Spanish Ministry of Science and Innovation (ISCIII Health Research Fund), and is part of the Spanish Network of Multiple Sclerosis (REEM). In addition, the Neuroimmunology Group has extensive experience in implementing phase II and III clinical trials using diverse immunomodulatory therapies on MS patients. The team comprises a principal investigator, three clinical researchers, and an advanced clinical practice nurse, who coordinates the clinical trials.

Main Publications

• Ois A, Vivas E, Figueras-Aguirre G, Guimaraens L, Cuadrado-Godia E, Avellaneda C, Bertran-Recasens B, Rodríguez-Campello A, Gracia MP, Villalba G, Saldaña J, Capellades J, Fernández-Candil JL, Roquer J. Misdiagnosis Worsens Prognosis in Subarachnoid Hemorrhage with Good Hunt and Hess Score. Stroke 2019; 50(11): 3072-3076. IF: 6.046. D1.

• Moreira A, Alari-Pahissa E, Munteis E, Vera A, Zabalza A, Llop M, Villarrubia N, Costa-García M, Álvarez-Lafuente R, Villar LM, López-Botet M, Martínez-Rodríguez JE. Adaptive features of natural killer cells in multiple sclerosis. Front Immunol 2019; 10: 2403. IF 4.716. Q2.



• Respuesta adaptativa mediada por células Natural Killer en la esclerosis múltiple- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI17/00254)- Period: from 2018 to 2020- Principal investigator: Martínez Rodríguez, José Enrique

See all Projects

Inflammatory and Cardiovascular Disorders Neuroimmunology

https://www.imim.es/programesrecerca/inflamacio/en_neuroimmunologia.html?n=&any=2019&enviar.x=57&enviar.y=21&t=publicacions&g=109

https://www.imim.es/programesrecerca/inflamacio/en_neuroimmunologia.html?t=projectes&g=109


Inflammatory and Cardiovascular Disorders Neuroimmunology


• Red Española de Esclerosis Múltiple- Financing institutions: Instituto de Salud Carlos III, European Regional

Development Fund (Grant RD16/0015/0011) the Ministerio de Economía y Competitividad

- Principal investigator: López-Botet, Miguel


• A phase III, multi-centre, randomised, double-blind, placebo-controlled, parallel-group clinical trial to investigate the efficacy and safety of BX-1 for the symptomatic relief of spasticity in patients with multiple sclerosis

- Protocol: DroSpas-1- Sponsor: BIONORICA- Budget: 36,500 €- Principal investigator: Martínez Rodríguez, José Enrique

• Estudio observacional transversal con recogida de datos retrospectivos para valorar el impacto económico de la Esclerosis Múltiple Secundaria Progresiva

- Protocol: CBAF312AES01 / NOV-EMS-2019-01- Sponsor: Novartis Farmacéutica, S.A.- Budget: 2,925 €- Principal investigator: Martínez Rodríguez, José Enrique


• José Enrique Martínez Rodríguez. VII Jornada d’Actualització del Tractament i Diagnòstic de les Malaties Neurològiques més Prevalents: Esclerosi Múltiple. Societat Catalana de Neurologia. Mataró, November 2019.



NeurovascularRESEARCH GROUP

This is a clinical group involved in stroke research. Currently our group is included in the Red de Enfermedades Vasculares Cerebrales (INVICTUS PLUS) that is one of the main Spanish research networks. The strengths of our group are: first, our ongoing database named BASICMAR, that contains extensive demographic, epidemiological, clinical, and outcome data about all stroke patients (n=8,300) admitted to our hospital, and second, our large collection of blood sample of stroke patients for genetic and biomarkers studies (n=6,000). The two main research lines are:

Group LeaderJaume Roquer González

[email protected]

Members

Carla Avellaneda Gómez (Researcher)Elisa Cuadrado Godia (Researcher)Eva Giralt Steinhauer (Researcher)Jordi Jiménez Conde (Researcher)Ángel Javier Ois Santiago (Researcher)Ana María Rodríguez Campello (Researcher)Carolina Soriano Tárraga (Researcher)Eva Langa Muñoz (Technician)Uxue Lazcano Dobao (Technician)Irene Navalpotro Gómez (Technician)Gemma Romeral Ballester (Technician)Miguel Ángel Rubio Pérez (Technician)Rosa Maria Vivanco Hidalgo (Technician)


Inflammatory and Cardiovascular Disorders Neurovascular

1. Clinical research and biomarkers in stroke: epidemiology, natural history and vascular risk factors, stroke biomarkers, environmental and stroke, diet and stroke, neurosonology and neuro-imaging.

2. Genetic and stroke research: our unit is part of the International Stroke Genetics Consortium, which includes many international (USA, Europe) and national groups and of the GENESTROKE Consortium working to develop GWAS and EWAS studies and projects.

Main Publications

• Mola-Caminal M, Carrera C, Soriano-Tárraga C, Giralt-Steinhauer E, Díaz-Navarro RM, Tur S, Jiménez C, Medina-Dols A, Cullell N, Torres-Aguila NP, et al. PATJ low frequency variants are associated with worse ischemic stroke functional outcome: a genome-wide meta-analysis. Circulation Res 2019; 124: 114-120. IF 15.862. Q1.

• Marini S, Crawford K, Morotti A, Lee MJ, Pezzini A, Moomaw CJ, Flaherty ML, Montaner J, Roquer J, Jiménez-Conde J, Giralt-Steinhauer E, Elosua R, Cuadrado-Godia E, Soriano-Tarraga C, et al; International Stroke Genetics Consortium. Association of Apolipoprotein E With Intracerebral Hemorrhage Risk by Race/Ethnicity: A Meta-analysis. JAMA Neurol 2019; 76: 480-491. IF 12.321. D1.

• Roquer J, Vivanco-Hidalgo RM, Prats-Sánchez LL, Martínez-Domeño A, Guisado-Alonso D, Cuadrado-Godia E, Giralt Steinhauer E, Jiménez-Conde J, Rodríguez-Campello A, Martí-Fàbregas J, Ois A. Interaction of atrial fibrillation and antithrombotics on outcome in intracerebral hemorrhage. Neurology 2019; 93: e1820-e1829. IF 8.689. D1.

• Ois A, Vivas E, Figueras-Aguirre G, Guimaraens L, Cuadrado-Godia E, Avellaneda C, Bertran-Recasens B, Rodríguez-Campello A, Gracia MP, Villalba G, Saldaña J, Capellades J, Fernández-Candil JL, Roquer J. Misdiagnosis worsens prognosis in subarachnoid hemorrhage with good Hunt & Hess score. Stroke 2019; 50: 3072-3076. IF 6.058. D1.

• Vivanco-Hidalgo RM, Avellaneda-Gómez C, Dadvand P, Cirach M, Ois A, Gómez-González A, Rodríguez-Campello A, de Ceballos P, Basagaña X, Zabalza A, Sunyer J, Cuadrado-Godia E, Roquer J, Wellenius GA. Association of residential air pollution, noise, and greenspace with initial ischemic stroke severity. Environ Res 2019; 179 (PtA): 108725. IF 5.026. D1.


https://www.imim.es/programesrecerca/inflamacio/en_vascular.html?n=&any=2019&enviar.x=53&enviar.y=19&t=publicacions&g=30




• Evaluación a nivel poblacional del impacto de la contaminación atmosférica sobre la incidencia y pronóstico del ictus isquémico

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI18/00056)- Period: from 2019 to 2021 - Principal investigator: Roquer González, Jaume; Vivanco Hidalgo, Rosa M.

• Contribución de la epigenética en el pronóstico del ictus. Estudio de EWAS y Micro-RNAs circulantes

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI18/00022)- Period: from 2019 to 2021 - Principal investigator: Jiménez Conde, Jordi; Rodríguez Campello, Ana.

• The Chemical Optimization of Cerebral Embolectomy (CHOICE) Trial- Financing institution: Fundació La Marató de TV3 (20170732)- Period: from 2018 to 2021- Principal investigator: Cuadrado Godia, Elisa

See all Projects


• Red de Enfermedades Vasculares Cerebrales. INVICTUS PLUS.- Financing institution: Fondo de Investigación Sanitaria-ISCIII. Subprograma RETICS

(RD16/0019/0002)- Period: from 2016 to 2021- Principal investigator: Roquer González, Jaume


• Estudio internacional de fase 2, aleatorizado, doble ciego, controlado con placebo, de búsqueda de dosis adaptada a la respuesta, de BMS-986177, un inhibidor del factor XIa oral, para la prevención de los nuevos casos de ictus isquémico o de infarto cerebral silente en pacientes tratados con Aspirina y clopidogrel después de un ictus no hemorrágico agudo o un accidente isquémico transitorio (AIT)

- Protocol: CV010-031- Sponsor: Bristol-Myers Squibb International Corporation (BMSIC)- Budget: 144,000 €- Principal investigator: Rodríguez Campello, Ana María

https://www.imim.es/programesrecerca/inflamacio/en_vascular.html?t=projectes&g=30



• Registro nacional de hemorragias intracerebrales (ARICH) en relación al tratamiento anticoagulante

- Protocol: VHI-PRO-2019-01- Sponsor: Fundació Institut Recerca Hospital Vall d’Hebron- Budget: No economic compensation- Principal investigator: Rodríguez Campello, Ana María

Awards

• Jaume Roquer. TOP 20 award 2019 “Área de Sistema Nervioso”. Best neurological department 2019 in Spain. 20th Edition Hospitales TOP 20. Madrid, 18/12/19.

• European Certification by the European Stroke Organization. Hospital del Mar Stroke Center ESO. 11/12/19. First stroke center accredited in Spain.

Appointments

• Ana Rodríguez Campello. Secretary of the Stroke Group of the Societat Catalana de Neurologia.

• Ana Rodríguez Campello. National auditor of the European Stroke Organisation for acreditation of stroke units and stroke centers.


• Ana Rodríguez Campello. Ictus. Escola de Salut de la Barceloneta. Casal Gent Gran de la Barceloneta. Barcelona, 13 February 2019.



RehabilitationRESEARCH GROUP

The main research areas of the group are:

• Neurological rehabilitation: brain plasticity and motor recovery by developing new technologies as Virtual Reality and Music Supported Therapy in stroke patients.

• Sarcopenia and malnutrition: ultrasound assessment, exercise and nutritional interventions.

• Effects of physical training and exercise on cardiovascular disease, chronic respiratory disease, cancer and ageing – Prehabilitation programs.

• Dysphagia: assessment and therapeutic strategies.

• Development of telerehabilitation systems applied to neurological, pulmonary and cardiorespiratory diseases.

Group LeaderEsther Duarte Oller

[email protected]

Members

Roser Belmonte Martínez (Researcher)Maria Coll Molinos (Researcher)Ferran Escalada Recto (Researcher)Anna Guillén Solà (Researcher)Ester Marco Navarro (Researcher)Josep Maria Muniesa Portoles (Researcher)Mercè Piqueras Céspedes (Researcher)Marta Tejero Sánchez (Researcher)Monique Messaggi Sartor (Technician)


Inflammatory and Cardiovascular Disorders Rehabilitation

The group’s purpose is to enhance the interaction between basic and clinical sciences, and health services, with potential translational application, providing innovative and potentially effective treatment alternatives.

Main Publications

• Marco E, Sánchez-Rodríguez D, Dávalos-Yerovi NV, Duran X, Pascual EM, Muniesa JM, Rodríguez DA, Aguilera-Zubizarreta A, Escalada F, Duarte E. Malnutrition according to ESPEN consensus predicts hospitalizations and long-term mortality in rehabilitation patients with stable chronic obstructive pulmonary disease. Clinical Nutrition 2019; 38(5): 2180-2186. IF 6.402. Q1.

• Sánchez-Rodríguez D, Marco E, Schott AM, Rolland Y, Blain H, Vázquez-Ibar O, Escalada F, Duran X, Muniesa JM, Annweiler C. Malnutrition according to ESPEN definition predicts long-term mortality in general older population: findings from the EPIDOS study-Toulouse cohort. Clinical Nutrition 2019; 38(6): 2652-2658. IF 6.402. Q1.

• Dávalos-Yerovi V, Marco E, Sánchez-Rodríguez D, Guillen-Solà A, Duran X, Pascual EM, Muniesa JM, Escalada F, Duarte E. Sarcopenia according to the revised European consensus on definition and diagnosis (EWGSOP2) criteria predicts hospitalizations and long-term mortality in rehabilitation patients with stable chronic obstructive pulmonary disease. Journal of the American Medical Directors Association 2019; 20(8): 1047-1049. IF 4.899. Q1.

• Sánchez-Rodríguez D, Hope S, Piotrowicz K, Benoit F, Czesak J, Dallmeier D, Decker G, De Spiegeleer A, Højmann AH, Hrnciarikova D, Marco E, Mendes D, Meza D, Nascimento P, Rodrigues A, Surquin M, Toscano-Rico M, Vankova H, Vetrano DL, Gasowski J, Van Den Noortgate N, Landi F. Sarcopenia in Acute Care Patients: Protocol for the European Collaboration of Geriatric Surveys: Sarcopenia 9+ EAMA Project. J Am Med Dir Assoc 2019; 20(11): e1-e3. IF 4.899. Q1.

• Pujol-Blaya V, Salinas-Huertas S, Catasús ML, Pascual T, Belmonte R. Effectiveness of a precast adjustable compression system compared to multilayered compression bandages in the treatment of breast cancer-related lymphoedema: a randomized, single-blind clinical trial. Clinical Rehabilitation 2019; 33(4): 631-641. IF 2.738. Q1.



• The RETORNUS-2 Study: Impact of respiratory muscle training on swallowing in stroke patients with dysphagia

- Financing institution: Fondo de Investigación Sanitaria. ISCIII (PI16/01081)- Period: from 2017 to 2019- Principal investigator: Guillén Solà, Anna

https://www.imim.es/programesrecerca/inflamacio/en_rehabilitacio.html?n=&any=2019&enviar.x=33&enviar.y=17&t=publicacions&g=10



• Brain Connects: Brain connectivity during stroke recovery and rehabilitation- Financing institution: Fundació La Marató de TV3- Period: from 2018 to 2020- Principal Investigator: Duarte Oller, Esther

See all Projects


• The activity of the Rehabilitation Research Group (RERG) is carried out in collaboration with other IMIM research groups belonging to the Inflammatory and Cardiovascular Disorders Programme. We have also established collaborative projects with other international institutions, highlighting: SPECS-Pompeu Fabra University (Barcelona); Heinrich-Heine-Universität (Düsseldorf, Germany); Guger Technologies OEG (Austria); Tyromotion GMBH (Austria); Private ICT and Health Foundation (Mataró); Hospital Joan XXIII (Tarragona); Cognition and Brain Plasticity Group of the Biomedical Research Institute of Bellvitge (Barcelona), and Research Institute Hospital Vall d’Hebron (Barcelona). The RERG also participates in collaborative projects with Liège University (Liège, Belgium), Vrije Universiteit (Brussels, Belgium), Antwerp University (Antwerp, Belgium), European Centre for Disease Prevention and Control (ECDC), Centro Nacional de Epidemiología de España of the Instituto de Salud Carlos III (Madrid, Spain), and Cardiovascular Foundation of Colombia (Santander, Colombia).

Theses

• Grau Sánchez, Jennifer. Music-supported Therapy in the rehabilitation of motor deficits after stroke. Universitat de Barcelona

- Directors: Duarte Oller, Esther; Rodríguez-Fornells, Antoni- Date of defense: 11/01/2019

Awards

• Ester Marco. Best presentation award of the Catalan Society of Physical Medicine and Reahabilitation (SCMFiR) 2019. Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears. March 2019.

• Ester Marco Navarro. SORECAR Award for the best communication on cardiorespiratory rehabilitation. Sponsored by SANRO. 57th National Congress. Sociedad Española de Rehabilitación y Medicina Física. May 2019.

https://www.imim.es/programesrecerca/inflamacio/en_rehabilitacio.html?t=projectes&g=10



Appointments

• Esther Duarte. Head of the Department of Physical Medicine and Rehabilitation. Parc de Salut Mar. January 2019.

• Anna Guillén-Solà. Secretary of the Director Board, Catalan Society of Rehabiliation and Physical Medicine. June 2019.

• Ester Marco. Accreditation of Research by the Agència per la Qualitat del Sistema Universitari de Catalunya (AQU). June 2019.


• Esther Duarte. Fundació Ictus. Participation in advising people who have suffered a stroke and in the evaluation of projects to promote research on this disease.


Documents

Programme Inflammatory and Cardiovascular Disorders